A METABOLOMIC, STRUCTURAL AND FUNCTIONAL STUDY OF POLYCYSTIN1 AND NEPHROCYSTIN1 by V. Mannella
  
UNIVERSITÀ DEGLI STUDI DI MILANO 
 
SCUOLA DI DOTTORATO DI RICERCA IN  
SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE 
 
DOTTORATO DI RICERCA IN BIOCHIMICA, BIO/10 
 
CICLO XXV 
 
TESI DI DOTTORATO DI RICERCA  
svolta presso Fondazione Centro San Raffaele  
Centro di Genomica Traslazionale e Bioinformatica  
Biomolecular NMR Laboratory, Milano, Italia 
 
A metabolomic, structural and functional study of Polycystin1 and Nephrocystin1 
 
Mannella Valeria 
Matr. N. R08827 
Docente guida: Prof. Marcello Duranti 
 
Correlatrice: Dr.ssa Giovanna Musco 
 
 
Coordinatore del Dottorato: Prof. Francesco Bonomi 
 
 
ANNO ACCADEMICO 2011/2012 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
Index 
 
 Pag. 
 
1. ABSTRACT          4 
 
2. INTRODUCTION         9 
 
2.1 Cystic kidney diseases belong to ciliopathies      10 
2.2 Nephronopthisis          12 
2.3 Nephrocystin1 (NPHP1)         13 
2.4 Autosomal Dominant Polycystic Kidney Disease (ADPKD)    14 
2.5 Polycystin1 (PC1)          16 
 2.5.1 PC1 as “metabolic regulator”       18 
 2.5.2 PC1 interacts with nephrocystin1      21 
 
3. AIM OF THE THESIS        24 
 
4. MATERIALS AND METHODS       27 
 
4.1 Metabolomic experiments         28 
4.1.1 Sample preparation: Exometabolome, biofluids and tissues   28 
4.1.2 NMR spectra: acquisition, metabolites identification and quantification  29 
4.1.3 Statistical analysis: Principal Component Analysis (PCA) and Metabolomics 
Univariate and Multivariate Analysis (MUMA)      31 
4.1.4 
13
C glucose flux experiments in vivo: experimental procedure and NMR spectra, 
quantification and normalization of 
13
C glucose and 
13
C lactate peaks and data analysis 33 
4.1.5 Cells' treatment: Glucose starvation and Oligomycin treatment   36 
4.1.6 Proliferation assay        36 
4.1.7 ATP content quantification       37 
4.1.8 Western Blot Analysis        38 
4.1.9 Histology and immunohistochemistry      38 
 
4.2 Structure determination procedure        39 
4.2.1 Generation of Escherichia Coli expression constructs     39 
4.2.2 Expression of recombinant proteins in E. Coli     41 
4.2.3 Purification of recombinant proteins in E. Coli     41 
4.2.4 Circular dichroism (CD) experiments      43 
4.2.5 Protein resonances assignment for structure determination    44 
4.2.6 Chemical -shift Rosetta (CS- Rosetta)      45 
4.2.7 Dihedral angles: 3J(HNHα) calculation and TALOS+ prediction   46 
4.2.8 Determination of NOE restraints       48 
4.2.9 Structure calculation        49 
4.2.10 Dynamic information: 
15
N spin relaxation measurements    50 
4.2.11 Residual dipolar couplings (RDC)      53 
4.2.12 NMR titrations         54 
 
5. METABOLOMICS         56 
 
5.1 Metabolomic profiling of the exometabolome of WT and Pkd1 KO cells   57 
5.2 Pkd1 KO cells display the Warburg effect       61 
5.3 Additional experiments in support of metabolic dysfunction in Pkd1 KO cells  64 
5.3.1 Demonstration of the Warburg effect      64 
5.3.2 Proliferation and apoptosis in Pkd1 KO cells depend on glucose metabolism 66 
5.4 Treatment with drugs         66 
 2 
 
5.4.1 Exometabolome of MEF cells treated with drugs.     66 
5.4.2 Additional experiments to test the effects of the drugs on the signaling cascade and the 
related biological effects.        69 
5.5 In vivo experiments         70 
5.5.1 1D 
1
H NMR experiments of polar extracts deriving from lyophilized kidneys 71 
5.5.2 
13
 C glucose experiments: kinetic experiments and experiments after 40 minutes from 
glucose injection         73 
5.6 Treatment with 2- deoxy- glucose (2DG)       78 
 
6. STRUCTURE OF THE N-TERMINUS DOMAIN OF NPHP1   81 
 
6.1 The recombinant N-terminus of NPHP1 is soluble      82 
6.2 The N-terminus of NPHP1 is predicted to be a coiled coil domain    83 
6.3 The N-terminus of NPHP1 is thermostable and contains α-helices    84 
6.4 NMR experiments          85 
6.4.1 NPHP11-115 chemical shifts assignment      86 
6.4.2 3D structural model obtained with Chemical -Shift Rosetta (CS-Rosetta)  87 
6.4.3 Hydrogen–deuterium exchange       88 
6.4.4 Experimentally calculated phi angle and Talos + prediction   90 
6.4.5 
1
H-
1
H NOE pattern confirms the presence of α helices    92 
6.4.6 Structure calculation of NPHP11-115      93 
6.4.7 NPHP11-115 displays three structured regions     98 
6.5 The interaction with the coiled coil domain of PC1 (CC_PC1)    102 
6.5.1 The purification of the recombinantCC_PC1     102 
6.5.2 Titration of 6His-MBP-CC_PC1 into NPHP11-115     104 
 
7. DISCUSSION          106 
 
7.1 Metabolomics          107 
7.1.1 Metabolomic profiling of the exometabolome of Pkd1 KO and WT MEF cells 107 
7.1.2 -The Warburg effect occurs both in cellular model and in vivo   108 
7.1.3 Signaling cascade         109 
7.1.4 Treatments with drugs: Cells’ treatment with rapamycin, metformin and AICAR; 
Treatment with 2-deoxy-glucose (2DG)       110 
7.1.5 Conclusions and  future perspectives      111 
7.2 Structure of NPHP11-115         112 
7.2.1 NPHP11-115 structure         112 
7.2.2 Conclusions and future perspectives      114 
 
8. APPENDIX          115 
 
8.1 NMR appendix          116 
8.1.1 Chemical shift         116 
8.1.2 Magnetization transfer        118 
8.1.3 Nuclear Overhauser Enhancement (NOE)      120 
8.1.4 Monodimensional (1D) NMR experiments     121 
8.1.5 Bidimensional (2D) NMR experiments: 
1
H-
15
N HSQC, 
1
H-
1
H-TOCSY, 
1
H-
13
C HSQC 
and 
1
H- 
1
H NOESY         122 
8.1.6 Three-dimensional (3D) NMR experiments: HCCH-TOCSY, HNCA, HNCACB,  
HN(CO)CACB, HNCO, HNHA, CC(CO)NH,  HCC(CO)NH, 
1
H-
15
N-HSQC-NOESY, 
1
H-
13
C-HSQC-NOESY         126 
8.1.7 ARIA (Ambiguous Restraints for Interactive Assignment) software  131 
 
 
 3 
 
8.2 Metabolomics and metabonomics appendix      133 
 
8.2.1 Metabolomics and metabonomics       134 
8.2.2 Mass spectrometry (MS)        136 
8.2.3 Nuclear magnetic resonance (NMR)      137 
8.2.4 NMR spectra: 1D NMR spectra and 2D NMR spectra    137 
8.2.5 Data preprocessing: Normalization and scaling factor    141 
8.2.6 Data analysis: Unsupervised analysis, supervised analysis    143 
8.2.7 Identification of metabolites       144 
 
REFERENCES           146 
 
 
 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Abstract 
 
 
 5 
 
Nephronophthisis (NPHP) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
are two genetic renal cystic diseases that lead to End Stage Renal Disease (ESRD) in 
childhood or adolescence and at the late-middle age, respectively
1
. At present the mechanisms 
at the basis of cystogenesis in both diseases are poorly understood and pharmacological 
therapies are still lacking.  
On the one hand NPHP is characterized by kidney tubular atrophy and cysts formation 
occurring primarily at the cortico-medullary border, that leads to a reduction of kidneys 
volume. It is caused by mutations in 11 different genes. The most common form of NPHP is 
the juvenile one (NPHP type 1), which is caused, in most of the cases, by homozygous 
deletion of NPHP1 gene (2q13 chromosome). NPHP1 gene encodes for nephrocystin1 
(NPHP1), a 732 amino acids long cytoplasmatic protein. It presents a widespread expression, 
but the pathogenic consequences due to loss-of-function are mainly confined to the kidney. In 
particular, NPHP1 is localized to cell-cell junctions, cilia and cell-matrix adhesion sites and it 
is involved in signaling transduction, cell-cell adhesion and cell polarity
2-4
.  
On the other hand the hallmark of ADPKD is the formation of bilateral cysts that leads to an 
increase of kidneys volume weight
5,6
. The disease is caused by mutations in two genes: Pkd1 
gene (16p13.3 chromosome) which is mutated in 85% of cases and Pkd2 (4q21 chromosome) 
which is mutated in the remaining part of cases. These genes encode respectively for 
polycystin1 (PC1), a large plasma membrane receptor 4302 amino acids long and polycystin2 
(PC2), a 968 amino acids long calcium channel. The two proteins interact through their C-
terminal coiled coil domains and are involved in common signaling pathways, thus explaining 
the same phenotype
5,7,8
.  
In this thesis we focused our attention on two new possible roles of PC1: the regulation of 
metabolism and its interaction with NPHP1. To disentangle PC1 role as “metabolic regulator” 
and its possible interaction with NPHP1 through its coiled coil domain, we have selected 
nuclear magnetic resonance (NMR) spectroscopy as primary investigation technique. 
 
PC1 as metabolic regulator. During a routine culture of mouse embryonic fibroblasts (MEFs) 
our collaborators (Dr. Boletta’s group in San Raffaele Hospital, Milan, Italy) have observed 
that the knock out (Pkd1 KO) MEFs for PC1 acidify the medium faster than the wild type 
(WT) ones. This finding rises the hypothesis that PC1 is involved in the regulation of cellular 
metabolism. Hence, exploiting nuclear magnetic resonance (NMR) spectroscopy, we have 
applied a metabolomic approach in order to investigate the metabolic pathways and the 
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signaling cascade deregulated by the loss of PC1. Importantly, the metabolomic analysis was 
performed both in cells and in mouse kidneys (WT and Pkd1 KO) in order to compare the 
results both in vitro and in vivo. The analysis of the 1D 
1
H NMR spectra of the media 
conditioned by the Pkd1 KO and by the WT MEF cells (exometabolome) has highlighted 
some metabolic differences: the exometabolome of the Pkd1 KO MEF cells displays an 
increased content of lactate, glutamate and alanine, presenting features similar to tumor cell 
metabolism
9-11
whereas the exometabolome of the WT MEF cells has an increased content of 
choline, formate, glucose, glycine and pyruvate. The two metabolites that vary mostly 
between the two cell lines are glucose and lactate, as highlighted by PCA analysis. In 
particular Pkd1 KO MEF cells display a major consumption of glucose, which is in turn 
related to a major production of lactate, showing the aerobic glycolysis, also called Warburg 
effect, a metabolic hallmark usually observed in cancer cells. 
In order to prove the occurrence of the Warburg effect in vivo, Ksp-Cre: Pkd1
flox/- 
and 
Pkd1
flox/+
 mice
12 
were treated with uniformly labeled 
13
C glucose
13,14
. 
1
H-
13
C HSQC NMR 
spectra on the polar extracts of kidneys and livers (used as control organ) were acquired and 
analyzed in order to simplify the detection of the metabolic conversion of glucose into lactate. 
The Pkd1 KO kidneys displayed an increased content of glucose and lactate as compared to 
the WT ones, whereas livers did not display any difference. These results confirm that the 
aerobic glycolysis occurs also in vivo and is caused by the loss of functional PC1.  
In order to restore the metabolic basal condition, mice were treated with 2-deoxy-glucose 
(2DG), a drug able to block directly the glucose metabolism
15,16
. For testing the efficacy of 
the treatment, Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+
 mice were treated at the same time with 
13
C 
glucose and 2DG and the polar extracts of kidneys and livers were analyzed through 
1
H-
13
C 
HSQC NMR spectra. The Pkd1 KO kidneys treated with 2DG display a decrease of the 
lactate content, whereas the amount of glucose does not change, hence the treatment with 
2DG affects the glucose metabolism but not its uptake. Moreover, from the histological point 
of view, the treated Pkd1 KO kidneys show a reduction of the volume of cysts and 
consequently a reduction of the weight of the kidney, compared to the not treated Pkd1 KO 
kidneys. Pkd1 KO livers do not present any changes after treatment with 2DG. These data 
show that 2DG acts specifically on Pkd1 KO kidneys, improving both the altered metabolism 
and the histology of the Pkd1 KO kidneys, without involving other organs that, instead, 
express functional PC1 (eg. the liver). In conclusion, our findings indicate that PC1 acts as 
“metabolic regulator”, as shown by the analysis of the medium conditioned Pkd1 KO cells. In 
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particular Pkd1 KO cells and Pkd1 KO kidneys are affected by the Warburg effect, a 
metabolic hallmark of accelerated metabolism observed also in cancer cells. Moreover, the 
analysis of Pkd1 KO kidneys of Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+
 mice treated with 2DG  has 
highlighted an improvement of the Warburg effect and the renal histology. These preliminary 
results are very promising for a possible therapy for ADPKD patients and will be object of 
further in vivo studies. 
 
The coiled coil domain of PC1 does not interact with the N-terminus of NPHP1. We have 
recently demonstrated that one of the poly-proline motives, belonging to cytoplasmic C-
terminus of PC1, is a binding partner for SH3 domain of NPHP1 and this complex is involved 
in the regulation of apoptosis
17
. The weak affinity of the resulting complex, as indicated by 
the estimated dissociation constant (Kd=0.3 +/-0.02 mM), suggests that other proteins or other 
domains of the same proteins could contribute to the interaction. In particular, the presence of 
coiled coil domains at PC1 C-terminus and at NPHP1 N-terminus, suggests the formation of a 
more complex macromolecular system involving interactions of both coiled coils. In order to 
verify and to structurally characterize at atomic level the interactions between PC1 and 
NPHP1 we have applied NMR spectroscopy.  
The first 115 amino acids (13kDa) of NPHP1 were predicted to form a coiled domain by the 
Web Server PCOIL. The coiled coil domain is a α helical motif involved in homo and 
heteromultimerization
18
. Unexpectedly, recombinant NPHP11-115 behaves as a monomer, as 
assessed by the elution volume in size exclusion chromatography and by the overall 
correlation time deduced from NMR relaxation experiments. Circular dichroism e periments  
confirmed the presence of   45% of α heli  and indicated a high thermostability of the domain, 
with a melting temperature of 65°C. 
The solution structure of the domain  shows that the first 115 amino acids of NPHP1 present a 
three helix bundle fold stabilized by hydrophobic interactions. The supposed interaction 
between the N-terminus of NPHP1 and the coiled coil domain of PC1 (CC_PC1) was next 
verified performing an NMR titration with the purified recombinant proteins, recording 
1
H-
15
N HSQC NMR spectra of NPHP1 upon addition of unlabelled CC-PC1. CC_PC1 was 
produced with the tags in order to improve the solubility and to avoid aggregation
19
. The 
recorded 
1
H -
15
N HSQC spectrum does not show any chemical shift displacement, indicating, 
that the two proteins do not interact. 
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In conclusion our data show that the N-terminus of NPHP1 is a monomeric and thermostable 
domain characterized by the presence of three α helices that pack together to form a three 
helix bundle. The N-terminus of NPHP1 is not a coiled coil domain, as erroneously predicted, 
and does not interact with CC_PC1. Interactions between NPHP1-115 and PC1 should be 
modulated by other protein domains or might involve additional proteins. Further experiments 
are needed to clarify this point. 
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2. Introduction 
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2.1. Cystic kidney diseases belong to ciliopathies 
 
 
Cystic kidney diseases (CKD) are a group of monogenic kidney diseases that are among the 
most frequent lethal genetic diseases in humans
1
. CKD are divided into autosomal dominant 
and autosomal recessive forms. The first one is characterized by End-Stage Renal Disease 
(ESRD) in adulthood, whereby the most prominent example is represented by Autosomal 
Dominant Polycystic Kidney Disease (ADPKD); the second one, comprising nephronopthisis 
(NPHP) and the Autosomal Recessive Polycystic Kidney Disease (ARPKD), leads to ESRD 
in childhood or adolescence
1
. 
CKD are classified as ciliopathies, a novel class of human diseases caused by dysfunction of 
two physically and functionally associated organelles: the centrosome and the cilia
20
. Indeed 
the products of all the genes (the so called cystoproteins) mutated in CKD both in humans, in 
mice and in zebrafish, are expressed in primary cilia (a sensory organelles), in basal bodies or 
in centrosomes. The ciliary expression of cystoproteins in the ciliated cells of many organs, 
such as the retina, explains the involvement of other organs in patients with cystic kidney 
disease. 
The cilium is composed of a microtubule-based core structure, the axoneme, composed by 
nine parallel doublet microtubules known as outer doublets, which elongate from the basal 
body, which is on turn surrounded by a ciliary membrane that is the continuation of the 
plasma membrane. There are two types of cilia: the primary cilium and the motile cilia
21
. The 
primary cilium is not motile and it is found on the apical surface of the majority of cells in the 
human body. It connects the physical and biochemical extracellular signals with the 
mechanism of cell-cycle and epithelial cell polarity
22
. Motile cilia are highly present on the 
epithelial cell surfaces of the trachea and oviduct, and cooperatively beat in wave-like patterns 
to generate fluid movement. To drive their bending motion, motile cilia have two extra 
microtubules in the centre of axoneme, termed central pair, as well as radial spokes and 
dynein arms attached to microtubule doublets as shown in Figure 1. The primary cilia are 
located in the apical surface of epithelial cells of kidneys. Their role is to perceive the flow of 
urine to modulate the duct morphogenesis [Figure 2]. 
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Figure 1. Architecture of cilia (primary and motile) and the basal body. [Figure from Yoder J., 2007, J 
Am. Soc. Nephrol.]. 
 
 
 
 
Figure 2. The primary cilium is in the apical part of epithelial cells of kidneys. The cilium responds to flow 
of urine and proteins associated, such as Polycystin1, Polycystin2 and Nephrocystin1, activate signaling cascade 
in response. [Figure from Hildebrandt F. et al. , 2011, N. Engl. J. Med.]. 
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2.2. Nephronophthisis 
 
 
Nephronopthisis (NPHP) was described for the first time in 1945 by Smith and Graham who 
called this disease “medullary cystic kidney disease”. In 1951 Fanconi et al. introduced the 
modern definition of this disease, “familial juvenile nephronophthisis” 3. The term 
“nephronophthisis” derives from the Greek and means “disintegration of nephron” describing 
one aspect of the histopathology of this disease. Indeed, the kidneys affected by NPHP show 
tubular atrophy with thickened tubular basement membrane, diffuse and severe interstitial 
fibrosis, development of cysts at the cortico-medullary junction. Cysts derive from collecting 
ducts and distal tubules
23
, leading to a possible reduction of the size of the kidneys [Figure 3]. 
Nephronopthisis is an autosomal recessive nephropathy that affects about 1/100000 live births 
and it is the most common cause of the ESRD in children and adolescents. Based on the age 
of onset of ESRD, three distinct forms of the disease are known: infantile, juvenile and 
adolescent; the most common form is the juvenile one in which ESRD occurs at a mean age 
of 13 years. In the adolescent form the ESRD onsets at a mean age of 19 years, in the infantile 
one the ESRD onsets at a mean age of 1 year
3
. 
Patients affected by NPHP display the following symptoms: polyuria, polydipsia, secondary 
enuresis, growth retardation and anemia. The 10-15% of juvenile NPHP patients present also 
extra-renal anomalies such as retinal degeneration, cerebellar vermis aplasia, liver fibrosis and 
cone shaped epiphyses. NPHP is caused by mutations in 11 different genes called NPHP 1-
11, which encode for nephrocystins, a family of cytoplasmatic proteins that are conserved 
among the evolution
3
. 
 
 
 
Figure 3. A section of human kidneys. On the left a normal kidney and on the right a kidney affected by 
NPHP. The volume of kidney affected by NPHP is reduced compared to the healthy one [Figure from Solliday 
M. et al., 2004, Atlas of Clinical Urology]. 
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2.3. Nephrocystin1 (NPHP1) 
 
 
The most common form of juvenile NPHP is caused by mutation in NPHP1 (2q13) gene that 
encodes for nephrocystin1 (NPHP1)
22
. Human NPHP1 is a cytoplasmatic protein 732 amino 
acids long, whose function remains still poorly understood. It is supposed to have a possible 
role in the regulation of cell-cell adhesion, in agreement with the localization in the primary 
cilium and at the cell-cell junctions
4
. 
NPHP1 contains a putative N-terminal coiled coil domain, a Src homology 3 (SH3) domain 
and a nephrocystin homology domain (NHD). These domains are separated by short, poorly 
conserved stretches rich in glutamic acid residues [Figure 4].  
 
 
 
Figure 4. A schematic representation of NPHP1, a 732 aa long cytoplasmatic protein. It contains a coiled 
coil domain, an SH3 domain flanked by two glutamic acid rich regions (grey box) and a highly conserved C-
terminal NHD domain [Figure from Saunier S. et al., 2005, Curr. Opin. Genet. Dev.]. 
 
 
The first 115 amino acids are predicted to form a short coiled coil domain
24,25
, a structure 
usually involved in homo/hetero association
18
. The SH3 domain spans from 157 to 207 
residue and it is an important module for binding protein: in particular it recognizes proline-
rich motifs
26
. The NHD domain occupies the two-third of the protein at C terminus and 
appears to represent a unique structural and functional protein domain for all nephrocystin 
proteins. This motif is involved in mediating both self-association and interaction with actin-
binding protein of the filamin family
4
. 
Comparison of human and mouse sequences indicates that the N-terminal region of a putative 
coiled coil domain and the nearby SH3 domain are well conserved, showing 80% amino acid 
identity. The long C-terminus is better conserved  displaying the 87% of amino acids identity, 
probably this domain also has an important function conserved throughout evolution
27
. 
The combination of SH3 domain with a coiled coil structure suggests that NPHP1 functions 
as an adapter protein belonging to a larger protein complex
4
. Independent studies have shown 
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that NPHP1 interacts with other nephrocystins, in particular nephrocystin4 and inversin 
(nephrocystin2), forming a nephrocystin complex. This complex simultaneously contacts both 
signaling proteins involved in the regulation of cell adhesion, such as the adaptor protein 
p130Cas, the protein kinase Pyk2, the activated ACDC42 kinase 1 (ACK), and proteins 
associated directly with the microtubular and actin cytoskeleton, such as tensin and 
filamin
4,28,29
. 
Notably, NPHP1 interacts with and is regulated by NPHP4
29
. The complex formed by 
NPHP1/NPHP4 interacts with the tight junction and polarity proteins including protein 
associated Lin 7 (PALS1), PALS1 associated tight junction protein (PATJ), and Par6 to form 
epithelial tight junction and to regulate epithelial morphogenesis
28
. It forms a bigger complex 
including further signaling and scaffolding proteins, such as Pyk2 and p130Cas. On the other 
hand, NPHP4 regulates the phosphorylation of tyrosines of NPHP1 by Pyk2. The interaction 
between NPHP1 and Pyk2 is essential to translocate Pyk2 from cytoplasm to cells matrix 
adhesion in response to extracellular signals
27
. 
 
 
 
2.4. Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
 
 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a slowly progressive genetic 
disease and affects about 1-2/1000 live births
30
. It is characterized by the progressive 
formation and enlargement of renal fluid-filled cysts [Figure 5] leading to ERSD by late 
middle age. Thousands of large, spherical cysts of various sizes are formed in the cortex and 
medulla zone of the kidneys but also in other organs such as liver, intestine and pancreas. 
Cysts formation is due to an abnormal proliferation of the epithelial cells leading to the 
alteration of the architecture of kidney failing blood filtration
6
. 
The first symptoms of the disease are micro- and macro-hematuria, back pain and 
hypertension
6
. ADPKD arises as consequence of mutations in two genes: PKD1 and PKD2, 
respectively encoding for polycystin1 (PC1) and polycystin2 (PC2)
30
. 
The gene PKD1 (locus 16p13.3) is mutated in 85-90% of the patients and leads to ESRD 
around 54 years; mutations in the gene PKD2 (locus 4q21-23) have been observed in the rest 
of the cases and lead to ESRD around the age of 74 years
31
. 
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Despite the fact that the disease is inherited in autosomal dominant manner, the analysis of the 
epithelial cells from renal cysts indicates that cystogenesis requires mutations of both alleles, 
leading to homologous loss of function of either PKD1 or PKD2
32
. This is known as the “two 
hit” model of cystogenesis [Figure 6]. The somatic “second hit” is believed to involve a single 
cell, which clonally proliferates, generating a cyst
32
. Hence each cyst arises as a consequence 
of a distinct somatic mutation event, e plaining the disease’s slow progression over the course 
of decades
33
. 
 
 
 
Figure 5. Comparison of normal and ADPKD kidney. On the left a normal kidney, on the right a kidney 
affected by ADPKD. The fluid filled cysts are evident and lead to increase in volume and weight of the organ 
[from PKD Fondation]. 
 
 
 
 
Figure 6. Comparison of healthy and cystic nephron. On the left and on the right a healthy and a cystic 
nephron, respectively. The somatic mutation in an heterozygous epithelial cell leads to cysts formation, resulting 
therefore caused by a local clonal event relating to a single cell [Figure from Qian F. et al.,1996, Cell.]. 
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This model, in which cysts originate from cells that have undergone the second mutation, can 
also explain why only some points present cysts without involving the whole nephron. 
Trans heterozygosity could also lead to disease, indeed patients with mutations in PKD2 
presents mutations also in PKD1 gene
34,35
. The PKD1 gene is larger than PKD2 and, for this 
reason, it shows a major frequency of mutations. These two genes encode for two 
transmembrane proteins, in particular PKD1 encodes for a large membrane receptor, 
polycystin1 (4302 amino acids) and PKD2 encodes for polycystin2 (968 amino acids), a non 
selective cation channel with preference for calcium. These two proteins colocalize in the 
primary cilium, interact through the respective C-terminal coiled coil domains regulating the 
influx of calcium and the consequent signal cascade 
8,36
. In the following a brief overview on 
the structure and function of PC1 will be presented. 
 
 
 
2.5. Polycystin1 (PC1) 
 
 
Polycystin1 (PC1) is a 4302 amino acids long membrane receptor, with a long N-terminal 
portion of  3000 amino acids, 11 transmembrane domains and a short intracellular C-tail of   
198 amino acids. It is believed that PC1 plays a role in cell-cell/matrix interactions, where the 
long extracellular domain can homodimerize and serve as ligand. In addition PC1 functions as 
a mechanosensor on the primary cilium and at cell-cell junctions
5
. The N-terminus contains a 
novel combination of protein-protein interacting domains, including leucine-rich repeats 
(LRRs), a C-type lectin domain, 16 PKD repeats (IgG-like domain) and a REJ domain, whose 
name derives from its homology with the sea urchin Receptor for Egg Jelly
37
. PC1 molecular 
mass is ~ 462 kDa, however the high glycosylation level leads to a final mass of 520 kDa
38
. 
The protein contains a G-protein coupled receptor proteolytic site (GPS), located between the 
N-terminal and the first transmembrane domain, an auto-proteolytic site that leads to the 
cleavage of PC1 in two fragments: an N-terminal fragment (NTF,  400 kDa), corresponding to 
the extracellular portion of protein, and a C-terminal fragment (CTF,   150 kDa), composed 
by the rest of the protein. The cleaved NTF can be either released or remain bound to CTF. 
Not all PC1 proteins present in the cells undergo to the cleavage at the GPS and the full length 
uncleaved protein co-exists with the cleaved version in cells 
39
. In vitro and in vivo studies 
have demonstrated that the cleavage at GPS site is essential for the correct functioning of 
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PC1
5
. Mice with mutations in the consensus site for cleavage HLT (cutting position is 
between L and T) that prevent it, survive to birth but they develop ADPKD at the first weeks 
of life that lead to death. The cleavage of PC1 is essential to prevent cystogenesis in the duct 
of distal and collector tubule [Figure 7]. 
 
 
 
Figure 7. A schematic representation of polycystin1 (PC1). This large transmembrane receptor undergoes a 
series of cleavage events that generate several different species co-existing within the same cell and carrying out 
distinct functions. The protein exists as an uncleaved polypeptide of 4302 amino acids (aa) (I) and can be 
cleaved at its G-protein coupled proteolytic site, generating an N-terminal fragment (NTF) that can be released 
(II) or remain tethered to the C-terminal fragment (CTF) (III). Also the C-tail (CTT) is cleaved, but the cleavage 
sites are still unknown, releasing the CTT fragment (IV) or the last 112 aa (V) [Figure from Boletta A., 2009, 
Pathogenics]. 
 
 
The intracellular C-terminal tail is involved in signaling transduction pathways, such as Wnt 
pathway, calcium signaling, G protein signaling and activation of STAT1 and STAT6. Also 
the C terminus is cleaved in two fragments: one that contains all C terminus of ~ 28-34 kDa 
and another one of ~ 16 kDa, the sites of cleavage are unknown
5
. Both the fragments interact 
with transcription factors, including β-catenin and STAT6, respectively, that are transported 
in the nucleus
40
. The C-tail contains putative phosphorylation sites that undergo 
phosphorylation, as demonstrated by in vitro assays, but the function is still unknown
5
.  
Moreover, the C-terminus of PC1 contains a coiled coil domain that mediates the interaction 
with a coiled coil domain located at the C terminus of PC2
8,36
, a non-selective cation channel 
with preference for calcium, regulating its activity. The PC1/PC2 complex regulates a number 
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of different biological processes including cell proliferation, apoptosis, cell migration and 
tubulogenesis [Figure 8].  
 
 
 
Figure 8. A schematic representation of PC1 and PC2. These transmembrane proteins interact through the 
coiled coil domain located in their cytoplasmatic C-terminal tail. This interaction regulates the influx of calcium 
from extracellular compartment. [Figure from Boletta A., 2009, Pathogenics]. 
 
 
 
2.5.1 PC1 as “metabolic regulator” 
 
 
PC1 is supposed to be involved in the regulation of the cellular metabolism. This hypothesis 
starts from a serendipitous observation of our collaborators (Dr. Boletta’s group in San 
Raffaele Hospital, Milan). During a routine culture of mouse embryonic fibroblasts (MEFs) 
they have observed that the knock out (KO) MEFs for PC1 acidify faster the medium than the 
wild type (WT) ones, as shown in Figure 9. 
Moreover the KO cells’ phenotype is quite different than WT ones, indeed they present an 
increase of the cellular size and proliferation rate. These phenotypic changes and the fast 
acidification of the medium could be related to an enhanced activity of mammalian target of 
rapamycin (mTOR) that is regulates negatively by PC1, as demonstrated by recent study
41
. 
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Figure 9. The culture medium of Pkd1
-/-
 KO MEF cell (on the right) is more acid than the one from WT (on the 
left) [provided by Boletta's lab]. 
 
 
PC1 controls the ERK-dependent phosphorylation of tuberin (Tsc2), upstream mTOR. The 
result is the downregulation of mTOR and of its downstream targets 
41
. Whereas the loss of 
PC1 leads to an up regulation of the ERKs pathway and consequentially the enhanced of 
mTOR activity and the relative downstream targets [Figure 10]. 
mTOR is a serine/threonine kinase that forms two complexes complex 1 (mTORC1) and 2 
(mTORC2). These complexes share some proteins but others are specific for each complex
42
. 
These complexes have different sensibility to inhibition due to rapamycin, a macrolide with 
an immunosuppressant and antiproliferative activity. In particular mTORC1 is very sensitive 
to rapamycin whereas mTORC2 is inhibited only by a great amount of drug or after a long-
term treatment
42
. 
mTORC1 and mTORC2 regulate different cellular activity. mTORC1 promotes cell growth 
(increase of cellular size) and cell proliferation (increase of cell number) acting as a 
“metabolic sensor” ensuring the optimal conditions for both cell growth and proliferation. Its 
activity is regulated by the availability of amino acids, growth factors, energy stores and 
oxygen
43
. mTORC2 modulates cell survival, cell polarity and cytoskeletal organization
43
. The 
upstream events that control mTORC2 are still poorly understood although growth factors 
appear to stimulate also mTORC2
43
 [Figure 11]. 
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Figure 10. Model for the regulation of tuberin and mTOR pathway by PC1. PC1 induces the activation 
of the PI3k/Akt pathway but the pool of Akt activated in response to PC1 is not able to phosphorylate Tsc2. 
At the same time PC1 over expression downregulates the MEK/ERK pathway resulting in reduced 
phosphorylation of tuberin and thus inhibition of mTOR. In ADPKD, the absence of PC1 would result in the 
up regulation of ERKs responsible for upregulating the mTOR pathway [Figure from Di Stefano et al., 2009, 
Mol. Cell. Biol.]. 
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Figure 11. mTORC1 and mTORC2. The upper part of the panel describes the network of mTORC1 and 
mTORC2. The dark grey boxes are the upstream signal that regulates the activities of these complexes, the light 
grey the downstream signal regulates by them. The lower part of the panel lists the proteins and the relative 
functions that form the mTOR complexes [Figure adapted from Laplante M., et al., 2012, Cell.] 
 
 
 
2.5.2 PC1 interacts with NPHP1 
 
 
PC1 and NPHP1 localize to identical subcellular compartment and we have recently 
demonstrated the interaction between these two proteins, in particular the SH3 domain of 
NPHP1 interact with PP2, one of the two poly proline motives present in the C-terminus of 
PC1. The interaction has been demonstrated both in vitro, through GST pull down and NMR 
titration and in vivo through co-immunoprecipitation
17
. 
From the biological point of view the complex appears to be involved in the regulation of 
apoptosis indeed studies have shown that kidneys from patients affected by ADPKD
44
 or by 
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NPHP
17
 display an increase of the apoptotic rate. NPHP1 could act downstream or in parallel 
with PC1for regulating apoptosis [Figure 12]. 
 
 
 
Figure 12. PC1 is able to inhibit both proliferation, acting on mTOR regulation, and apoptosis. For the 
inhibition of proliferation NPHP1 is not required whereas the regulation of apoptosis requires NPHP1 which 
could act downstream (left) or in parallel (right) to PC1 [Figure from Wodarczyk C. et al., 2010, PlosOne]. 
 
 
The affinity of the resulting complex is low with an estimated dissociation constant, measured 
by nuclear magnetic resonance (NMR), of about 0.3 +/- 0.2 mM. This low value indicates that 
the complex is not stable. For stabilizing the complex probably other proteins or other 
domains of the same proteins could be involved in the interaction. Indeed both proteins 
present a coiled coil domain, usually involved in protein-protein interaction
18
. In detail the N-
terminus of NPHP1 (the first 115 amino acids) is predicted to be a coiled coil domain and the 
C-terminus of PC1 contains a coiled coil structure [Figure 13]. Hence, in addition to the 
interaction between the SH3 domain of NPHP1 and the PP2 of PC1, these two proteins could 
interact together through the coiled coil domains in order to stabilize the complex. 
Overall it is hypothesized that the formation of the complex between NPHP1 and PC1 might 
uncover the link between two unrelated CKD supporting the notion that common pathogenic 
defects underlie to renal cysts formation.  
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Figure 13. The scheme of the interactions between NPHP1 and PC1. NPHP1 (top) interacts via SH3 domain 
with one of the two poly proline domains of the PC1. The resulting complex is not stable, hence we hypothesize 
that the coiled coil (CC) domain of the PC1 and the putative coiled coil (putCC) domain of the NPHP1 could 
interact to stabilize the complex. 
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3. Aim of the thesis 
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Despite the numerous reports on ADPKD the molecular mechanisms of cystogenesis are still 
poorly understood, hence a complete knowledge on all pathways regulated by PC1 is still 
lacking. For this reason, at present a pharmacological therapy for the treatment of this genetic 
renal disease is still lacking. 
We focused our work on two new possible roles of PC1: the regulation of metabolism and its 
interaction with NPHP1. 
The hypothesis that PC1 could act as “metabolic regulator” stems from the serendipitous 
observation of our collaborators, Dr. Boletta in San Raffaele Hospital, Milan. During a 
routine cellular culture they have observed that Pkd1 KO MEF cells acidify faster the medium 
than the WT ones, because of an increased  lactate production in Pkd1 KO cells. This effect 
could indicate an accelerated metabolism of these cells correlated to an increased cell size and 
proliferation rate. These features are linked probably to the enhanced activity of mammalian 
complex of rapamycin (mTOR). Indeed a previous study
41
 has demonstrated that the loss of 
PC1 leads to an upregulation of ERKs pathway and a consequent increase of mTOR activity. 
The hypothesis that the interaction between PC1 and NPHP1 might be mediated by the coiled 
coil motifs present in both proteins originated from our previous study
17
. We have 
demonstrated that one of the two poly proline motifs present at the C- terminus of PC1 
interacts with low affinity with the SH3 domain of NPHP1 regulating apoptosis. This result 
uncovers a link between the two different ciliopathies, ADPKD and NPHP, supporting the 
notion that common pathogenetic defects underlie renal cyst formation. Because of the weak 
interaction between SH3 domain of NPHP1 and the poly proline motif of PC1 we hypothesize 
that the coiled coil domains of both NPHP1 and PC1 interact to stabilize the complex. 
To disentangle PC1 role “metabolic regulator” and its possible interaction with NPHP1 
through its coiled coil domain, we have selected nuclear magnetic resonance (NMR) 
spectroscopy as primary investigation technique. 
We have used a metabolomic approach to study the metabolic changes induced by the 
absence of PC1 analyzing both the extracellular medium conditioned by the presence of KO 
and WT cells. To confirm in vivo the data obtained in cellular model we also analyzed the 
kidneys, deriving from mouse model of the disease.  
In the second part of the thesis we applied NMR to characterize at the atomic level the three 
dimensional structure of the coiled coil domain of NPHP1 and to verify and characterize its 
interaction with the coiled coil domain of PC1. 
In summary, the aims of the thesis are the following: 
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 investigation of the metabolic pathways deregulated by the loss of PC1 and 
characterization of the related signaling cascade both in cells and in kidneys in order to 
find a possible target for pharmacological treatment; 
 
 determination of the structure of the putative coiled coil domain of the NPHP1; 
 
 determination of the interaction of NPHP1 with the coiled coil domain of PC1. 
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4. Materials and methods 
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4.1. Metabolomic experimental procedure 
 
 
4.1.1 Sample preparation 
 
 
Exometabolome. Pkd1 KO and WT mouse embryonic fibroblasts (MEFs)
41
 were grown in 
DMEM (Gibco) + 10% of Fetal Bovine Serum (FBS) (Euroclone). The medium was collected 
one day after cellular confluence, centrifuged at 4°C at 13000 rpm to precipitate the cells in 
order to avoid to aspirate them, and stored at -80°C. The conditional cells Pkd1 
flox/flox 
MEFs
41
 
were grown in the same manner previously described but they underwent the treatment with 
10 μM of a recombinant TAT-Cre protein (Excellgen) for 2 hours with 100 mM of 
chloroquine (SIGMA) in absence of serum, in order to inactivate the Pkd1 gene preventing 
any integration within the genome and for avoiding clonally effects. 
For experiments aiming to investigate the effect of drug treatment on the metabolism MEFs 
cells were treated separately with 20 or 50 nM of rapamycin (SIGMA), 2 mM of metformin 
or 2 mM of AICAR. After cellular confluence, the cells were treated for 48 hours with drugs 
before to collect the medium.  
In all e periments 530 μl of e tracellular medium were mi ed with 60 μl of deuterated 
phosphate buffer containing DSS (final concentration 150 mM) and 10 μl of NaN3 1,2%. The 
final volume of sample for NMR acquisition was 600 μl. 
 
 
Biofluids: urine and serum. A volume of 15 μl of serum was collected from mice Ksp-Cre: 
Pkd1
flox/- 
and Pkd1
flox/+ 12
 and immediately centrifuged at 13000 rpm at 4°C to avoid 
coagulation.  
NMR samples were prepared mi ing 10 μl of serum with phosphate buffer (final 
concentration 180 mM), DSS (final concentration 90 μM), used as internal standard, and 
0,02% of NaN3. The final volume of the sample was 250 μl.  
Urine were taken directly from the bladder from mice Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+
 
12 
with 
a syringe and after centrifuge at 4°C at 13000 rpm to precipitate the cells. 
NMR samples were prepared mixing 25 μl of urine with deuterated phosphate buffer (final 
concentration 180 mM), DSS (final concentration 90 μM) and 10 μl of NaN3 1,2%. The final 
volume of the sample was 250 μl. 
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Metabolites extraction from tissues. Tissue samples were snap-frozen in liquid nitrogen and 
stored at -80°C until extraction. The frozen tissues were weighted before and after 
lyophilization (24 hours). Polar and apolar metabolites were extracted from the homogenous 
dry tissue powder using MeOH/CHCl3/H2O (2:2:1 v/v) solvent extraction strategy
45
. The 
lyophilized tissues were mechanically fragmented with the help of a spatula, then chloroform 
and methanol were added and samples were incubated in orbital agitation for 1 hour at 4°C. 
After incubation chloroform and water were added and samples were centrifuged in order to 
separate the polar (up) and the apolar (down) phases. The polar phases were placed in new 
vials and then lyophilized for 24 hours. 
For NMR samples the resulting powder was suspended in phosphate buffer (final 
concentration 150 mM), with addition of 100 mM DSS, and 5 μl of NaN3 1,2% mM. The 
final volume of each sample was 250 μl with 90:10 H2O:D2O ratio. 
 
 
 
4.1.2 NMR spectra: acquisition, metabolites identification and 
quantification 
 
 
NMR acquisition. NMR spectra were acquired using a 600 MHz spectrometer (Bruker 
Avance 600 Ultra Shield TM Plus, Bruker BioSpin) equipped with a triple-resonance TCI 
cryoprobe with a z shielded pulsed-field gradient coil. All experiments were carried out at 298 
K, spectrometer temperature was calibrated using pure methanol-d4 sample21. Sample 
temperature inside the spectrometer was equilibrated for 5 minutes before data acquisition. 
For all experiments continuous water presaturation with a RF of 35 Hz was applied during 
relaxation delay. Acquisition parameters for each type of sample are listed in Table 1. 
 
 
Metabolites identification: Metabominer and CCPN. Metabolites were identified using two 
tools based on spectral reference libraries of small molecules: Metabominer
46
 and CCPN 
Metabolomic project
47
. 
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Metabominer is a semi-automated tool to assist the user in the identification of metabolites in 
a complex mixture using a comprehensive 2D spectral reference library with a detailed 
knowledge of the metabolite composition of the common biofluids. The input is the peak list 
of the spectrum, the software draws a synthetic spectrum and, selecting the library of interest, 
it matches the experimental peak list with the peak list of the library. 
CCPN Metabolomic project, available for CCPNmr suite (it can be downloaded from the 
Collaborative Computing Project for NMR, 
http://www.ccpn.ac.uk/collaborations/metabolomics), consists of assigned 1D and 2D spectra 
of standard compounds according to the public database. The project is interactive, as the 
spectra of unknown mixtures can be easily superimposed and compared with the database 
spectra, thus facilitating their assignment and identification. In addition the database can be 
easily modified. 
 
 
Sample Experiments Dimension Number 
of scans 
Receiver 
gain 
Spectral 
window 
(Hz) 
Offset 
 
(ppm) 
Time 
domain 
Not treated 
Exometabolome 
1D 
1
H noesy 1H 128 50.8 12019 4.72 7372 
1D 
1
H cpmg 1H 128 50.8 10027 4.70 7372 
1
H
13
C HSQC 
1H 
48 181 
9615  4.70 2048 
13C 25655 75 350 
Treated 
Exometabolome 
1D 
1
H noesy 1H 72 50.8 7194 4.70 7372 
1D 
1
H cpmg 13C 128 50.8 7194 4.70 7372 
Urine 
1D 
1
H noesy 1H 96 71.8 12019 4.70 9830 
1D 
1
H cpmg 1H 128 50.8 10027 4.70 7372 
J-resolved 
1H 
24 71.8 
10000 4.70 1024 
1H 94 4.70 40 
1
H
13
C HSQC 
1H 
44 181 
9615 4.70 2048 
13C 25655 75 300 
1
H 
1
H Tocsy 
1H 
10 181 
7212 4.70 2048 
1H 7212 4.70 512 
Tissue 
1D 
1
H noesy 1H 320 10 7194 4.70 9830 
J-resolved 
1H 
20 10 
10000 4.70 1024 
1H 94 4.70 40 
1
H-
1
H Tocsy 
1H 
26 181 
7212 4.70 2048 
1H 6001 4.70 512 
Table 1: List of NMR experiments and relative parameters.  
Spectra were processed using Topspin NMR software from Bruker and Mnova software of Mestrelab
48
. 
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Metabolites quantification. For metabolites quantification we took advantage of the 
combination of (a) the algorithm called GSD (global spectrum deconvolution), available in 
the Mnova software package of Mestrelab
48
 and (b) of a quantitative referencing strategy, 
known as PULCON
49
. The GSD algorithm deconvolves overlapping regions in 
monodimensional spectra in order to obtain separate signals of  single metabolites, thus 
allowing measurement of their absolute integral. To convert the integral into absolute 
concentration an external standard, the reference, with known concentration (a tube with 0,5 
mM of DSS and 1 mM sucrose) was acquired and the PULCON equation (eq.1) was applied. 
 
 
conc
calA
conc
calA
sample
samplesample
ref
refref



        eq.1 
SINSRG
PT
cal



1
  
 
where A is the peak integral, cal is the parameters of acquisition of the spectrum and conc is 
the concentration. The cal parameter is obtained as function of the temperature of acquisition 
(T), the receiver gain (RG), the number of scans (NS), the size of real spectrum (SI) and the 
90° pulse length (P1). 
 
We have acquired both technical (samples deriving from the same cell culture) and biological 
(samples deriving from different cell cultures) replicates of the exometabolome of Pkd1 KO 
and WT MEF cells, treated or not with drugs, and of Pkd1 
flox/flox 
MEF cells. To obtain the 
concentration of the metabolites we have calculated the arithmetic average and the standard 
deviation of the technical replicates, normalized for the final number of cells in the well, and 
then, to account for the biological replicates and the different cellular growth, we have 
calculated the weighted average and the standard deviation of the weighted average.  
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4.1.3  Statistical analysis: Principal Component Analysis (PCA) and 
Metabolomics Univariate and Multivariate Analysis (MUMA)  
 
 
For statistical analysis we used the metabolites concentrations and applied the Pareto scaling 
of the variables (eq.2) prior to perform principal component analysis (PCA), a multivariate 
unsupervised statistical technique.  
 
i
iij
ij
s
xx
x

~  eq.2 
 
The value is converted as fluctuation around zero and scaled for the root square of the 
standard deviation. 
PCA gives a global view of the systematic variation of the data while reducing its 
dimensionality to few principal components (PC), which account for a large amount of the 
total variance between the NMR fingerprints. The final aim of PCA is to enable easy 
visualization of any clustering or similarity of the various samples. The results of PCA are 
presented in terms of score and loading plots. Samples with a similar metabolic footprint tend 
to cluster together in the score plot. Each PC is a weighted linear combination of the original 
descriptors and this information is shown in a loading plot. 
To perform the statistical analysis we used a home-made R software package called muma: 
Metabolomics Univariate and Multivariate Analysis (Gaude E. et.al., submitted). This user-
friendly package provides a pipeline for the whole process of metabolomics statistical 
analysis, from data pre-processing, to dataset exploration and visualization, to the 
identification of potentially interesting variables (or metabolites). To this aim, we 
implemented well-established multivariate statistical analysis such as PCA, partial least 
squares discriminant analysis (PLS-DA) and orthogonal projection to latent structures (OPLS-
DA) and univariate statistical techniques that are typically used in metabolomics analyses. 
The package assists the user in the results' interpretation with clear and ready-to-use graphical 
outputs. muma has been designed for the analysis of metabolomics data generated with 
different analytical platforms (NMR, MS, NIR) with a special focus on NMR data, providing 
dedicated tools such as Statistical TOtal Correlation Spectroscopy (STOCSY)
50
 and for Ratio 
Analysis of NMR spectroscopy (RANSY)
51
. 
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4.1.4 13C flux experiments in vivo 
 
 
Experimental procedure and NMR spectra. Litters Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+ 22
 at P8 
were treated injecting intracutaneously 1000 mg/Kg of uniformly labeled 
13
C- glucose (sigma 
Aldrich). 
A litter of 8 mice (4 KO and 4 WT) was used for kinetic experiments. Mice were sacrificed 
20, 40 and 60 minutes after the injection of 
13
C glucose and kidneys, liver, serum and urine 
were collected. The amount of 
13
C glucose and the relative 
13
C lactate produced was detected 
in the biofluids and in the tissues. 
KO and WT mice deriving from five different litters were sacrificed 40 minutes after the 
injection of 
13
C-glucose, kidneys and livers were collected, washed in PBS and snap-frozen in 
liquid nitrogen.  
KO and WT mice deriving from three different litters were used for experiments with 2-
deoxy-glucose (2DG) (Sigma Aldrich). 2DG or NaCl (as control) was injected 
intracutaneously into mice at 500 mg/Kg at P7 and P8, the second injection was followed by 
an injection with 1000 mg/Kg of 
13
C glucose finally kidneys and livers were collected.  
Tissues and biofluids were treated as described in paragraph 4.1.1. 
To detect the 
13
C-glucose and the relative products, especially 
13
C lactate, NMR spectra were 
acquired as described in the paragraph 4.1.2. The acquired experiments and the relative 
parameters are listed in Table 2. 
 
 
Sample Experiments Dimensions Number 
of scans 
Receiver 
gain 
Spectral 
windows 
(Hz) 
Offset 
 
(ppm) 
Time 
domain 
Urine, 
serum, 
tissues 
(liver and 
kidney) 
1D
1
H noesy 1H 64 45.2 7194 4.70 98304 
       
1D
13
C zgpg30 13C 290 181 29762 100 15360 
1
H
13
C HSQC 
1H 
2 45.2 
6602 4.70 1024 
13C  24146 80 400 
1
H
13
C HSQC 
1H 
3 181 
6602 4.71 1024 
13C  30183 100 400 
Table 2: List of acquired experiments and the relative parameters for 
13
C glucose experiments in vivo  
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Quantification and normalization of 
13
C glucose and 
13
C lactate peaks. For lactate and 
glucose quantification we have used 2D 
1
H-
13
C HSQC spectra. For lactate determination the 
peak at 1.32 ppm and 22.91 ppm, corresponding to the methyl (CH3) signal, was integrated. 
For glucose determination we have integrated the peaks corresponding to the methylene 
signal (C
6
H2), accounting for both α- and β-glucose (3.82, 3.78, 63.41 ppm; 3.89, 3.73, 63.47 
ppm). These characteristic peaks have been chosen because they are isolated in the spectrum. 
To convert the value of the peak integral into metabolite concentration we used an external 
standard, we therefore made a calibration curve using 
13
C-glucose. Spectra of home-made 
standards of 
13
C glucose at different concentrations: 20, 25, 40, 50, 75, 100, 250, 500 μM, 
were acquired. In detail, we acquired for each standard two 
1
H-
13
C HSQC that differ for the 
number of scans and the value of the receiver gain: one was acquired with a number of scans 
equal to 2 and the value of receiver gain of 45.2, the other one with 3 number of scans and 
181 of receiver gain The calibration curves were made acquiring spectra with different 
parameters because the experiments performed on tissues were acquired in different 
conditions. 
We have made two calibration curves [Figure 15] one for each set of 
1
H-
13
C HSQC. 
 
 
 
A 
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B 
 
Figure 15. The calibration curves of 
13
C glucose. The y axis represents the value of integral and the x axis the 
concentration of the standard. A The curve of 
1
H-
13
C HSQC acquired with NS 3 and RG 181, B the curve of 
1
H-
13
C HSQC acquired with NS 2 and RG 45.2. 
 
 
The equation to convert integrals into concentrations is linear y = mx, where y represents the 
integral and x the concentration, m is the conversion factor. The value of m is 2.248 for 
1
H-
13
C HSQC acquired with NS 3 and RG 181, whereas for 
1
H-
13
C HSQC acquired with NS 2 
and RG 45.2 m is 0.4346.  
This equation can be used to convert the integral of the methylene group of the glucose in 
concentration but not for the methyl group of the lactate as the CH2 and CH3 groups have 
different T1 relaxation rates and different 
1
JCH coupling.  
To find the conversion factor between CH3 and CH2 we made 11 standard 
12
C-glucose and 
12
C-lactate solutions (1:1 stoichiometry) at different concentrations (0.5, 1, 2, 3, 4, 5, 10, 20, 
40, 50 and 80 mM, respectively) and 
1
H
13
C HSQC spectra were acquired. For each spectrum 
and therefore concentration, the ratio between the integral of the –CH3 of the lactate and the –
CH2 of the glucose was calculated. The conversion factor was obtained from the average of 
the single ratio values. The obtained correction factor is 1.02. 
 
 
Data analysis. Absolute integrals of the methylene group of the glucose and of the methyl 
group of the lactate contained in kidneys and livers (I) were measured using the Data Analysis 
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module of MNova. Integrals were then divided by the dry weight (DW) of the corresponding 
tissue (IWT=IWT/DWWT; IKO=IKO/DWKO) to account for the different organ weights of WT and 
KO mice. Moreover, to account for the genetic variability within litters, for each KO mouse 
the integrals (IKO) of glucose and lactate peaks were normalized with respect to the integral of 
the corresponding WT littermate (IWT). Results for both glucose and lactate were therefore 
expressed as peaks integral ratio between KO and WT animals (R=IKO/IWT). To obtain a 
single value the average and the standard deviation of five litters were calculated. 
The effect of 2-deoxy-glucose (2DG) treatment was expressed as ratio (R2DG) between the 
integrals of glucose and lactate peaks of KO mice treated with 2- deoxy-glucose (IKO_2DG) and 
the integrals obtained from spectra performed on the corresponding KO littermates (IKO) 
treated only with NaCl (R2DG= IKO_2DG/IKO). To obtain a single value the average and the 
standard deviation of five litters were calculated. 
 
 
 
4.1.5 Cell’s treatment 
 
 
Glucose starvation. For glucose starvation experiments the composition of the medium is. 
Basic DMEM (Gibco) 2.3 g/L; Sodium Bicarbonate (Gibco) 3.7 g/L; L-glutamine (Gibco) 
0.584 g/L; serum 10% (Euroclone), pen-step 1% (Gibco) with or without glucose (Sigma) 4.5 
g/L .  
 
Oligomycin treatment. Cells were treated with oligomycin (Sigma Aldrich) at the final 
concentration of 30 μM for 48 hours. 
 
 
 
4.1.6 Proliferation assay 
 
 
For proliferation assays immunostaining was carried out using an anti-Ki67 antibody 
(Novocastra) at 1:400. For cells, fluorescence was measured on triplicates of 300 cells using 
the microscope Axioplot (Zeiss). For kidney sections, picture at 20x were taken using the 
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camera Axio MRc5 (Zeiss) with the microscope Axioplane 2 (Zeiss), positive cells were 
counted on 6 sections for each group for each experiment using ImageJ software. 
 
 
 
4.1.7 ATP content quantification 
 
 
For ATP content evaluation, whole cell extracts of control and treated MEFs cells were 
prepared by suspending pellets in lysis buffer as described in Distefano et al, 2009. 
Intracellular ATP quantification of lysates was measured on 250 ng of protein by luciferase 
activity as showed in the standard protocol present in ATP determination kit (Invitrogen). 
 
 
              
4.1.8 Western Blot Analysis 
 
 
For western blot analysis, the cells were suspended in lysis buffer (250 mM sucrose; 20 mM 
imidazole and 1mM EDTA, pH 7.4, 0.5% Triton-X 100, supplemented with Protease 
Inhibitors Cocktail (Amersham) and phosphatase inhibitors (1 mM final of glycerolphosphate, 
sodium orthovanadate and sodium fluoride). Total lysates were quantified and Laemmli 
buffer was added to reach a 1X final concentration. Proteins were resolved in a SDS-PAGE 
gel and transferred onto PVDF membranes. Next, 5% milk in TBS-T was used for incubations 
with primary antibodies. HRP-conjugated secondary antibodies (Roche) were visualized using 
the ECL System (Amersham), which were mixed with super-Femto ECL System (Pierce) 
when necessary. 
The primary antibodies used were: anti–p-AMPK-Thr172; anti-AMPK; anti-p-S6RP 
SER235/236; anti-S6Rp; anti-p-ERK T202/Y204 and anti-ERK (Cell signaling Technology) 
at 1:1000; anti-LC3 NB100 (Novus Biologicals), anti-actin and anti-tubulin (Sigma Aldrich) 
at 1:5000.  
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4.1.9 Histology and immunohistochemistry 
 
 
After sacrifice, kidneys were removed, washed in phosphate-buffered saline (PBS), weighted 
and fixed in 4% Paraformaldehyde (PFA). After incubation in a sucrose in PBS gradient scale 
from 10% to 30% samples were incubated in 10% glycerol (Sigma) in a mixture of OCT 
(BIO-OPTICA) and sucrose 30%, finally embedded in OCT. Criostat sections were air-dried 
1 hour, rehydrated in PBS, incubated in Harris Hematoxylin 1:10 (Sigma-Aldrich) for 2 
minutes, washed, incubated in Eosin G (BIO-OPTICA) for 7 minutes, washed dehydrated and 
mounted in DEPEX (Sigma). 
For immunohistochemistry 10 μm cryosections were washed in Tween 0.1% in PBS, fi ed in 
PFA 4%, permeabilized in Triton 0.1% in PBS, incubated in hydrogen peroxide 0.3 % for 30 
minutes, blocked for 1 hour at room temperature with 5% Normal Goat Serum (Sigma 
Aldrich), 3% Bovine Serum Albumine (BSA, Sigma Aldrich) in PBS, incubated over night at 
4°C with the antibody (Ab) in blocking buffer diluted at 1:500. Sections were then incubated 
with the Dako EnVisio+System-HRP (Dako). Staining is completed by an incubation with 
3.3’ diaminobenzidine tetrahydrochloride (DAB) DAB+ Substrate Chromogen System 
(DakoCytomation) and counterstained with Harris Hematoxylin (Sigma Aldrich) diluted 1/10 
for 3 min. 
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4.2. Structure determination methods 
 
 
4.2.1 Generation of Escherichia Coli expression constructs  
 
 
The plasmids for expression in Escherichia Coli of the putative coiled coil domain of the 
human NPHP1 (spanning the first 115 amino acids) and the coiled coil domain of PC1 
(CC_PC1) (spanning residues His 4186 - Ala 4257) were generated using a multi-step PCR-
based process.  
For NPHP1 the regions of interest were amplified from a pCDNA3.1 vector containing the 
cDNA of the entire sequence of the human NPHP1 protein (NCBI Reference Sequence: 
NM_000272.3).  
The CC_PC1 was amplified from a pXBlue vector that contains the cDNA of the entire C-
terminal tail of human PC1 (NCBI Reference Sequence: NM_001009944.2). Both plasmids 
were kindly provided by Dr. A. Boletta (San Raffaele Hospital, Milano, Italy). 
The forward primers of both constructs contain the NcoI restriction site and the reverse 
primers bear a stop codon followed by the KpnI restriction site. The sequences of the primers 
that were used are the following: 
 
 for NPHP1:  
NPHP1 1-115F: 5’CAT GCC ATG GGT ATG CTG GCG AGA CGA CAG 3' 
NPHP1 1-115R: 5' GG GGT ACC TTA GAT AGG TGC CCC AAC TTC AGT 3' 
 
 forCC_PC1: 
CC_PC1F: 5' CAT GCC ATG GGT CAC CCC TCC ACC TCC TCC 3' 
CC_PC1R: 5' GG GGT ACC TTA GGC GGG CGC CCG GCT GCT 3' 
 
The Polymerase Chain Reaction (PCR) mix was prepared with: DNA template (30 ng), Pfu 
buffer 10× (Promega), 10 mM of a mixture of equal quantities of the four dNTPs (Promega), 
1 mM of each of the two primers (synthesized by PRIMM, Italy), 3 U of Pfu DNA 
polymerase (Promega) and water to a final volume of 50 μl. 
The cycling parameters for PCR reaction were: 
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 for NPHP1 
1. 95°C for 2 minutes 
2. 95°C for 45 seconds 
3. 61°C (i.e., primer melting temperature, Tm, plus 2-3°C) for 30'' 
4. 72°C for 2' 
5. repeat steps 2-4 for 34 times 
6. hold at 4°C.  
 
 for CC_PC1 
1. 95°C for 2 minutes 
2. 95°C for 45 seconds 
3. 61°C (i.e., primer melting temperature, Tm, plus 2-3°C) for 30'' 
4. 72°C for 2' 
5. repeat steps 2-4 for 34 times 
6. hold at 4°C.  
 
The amplified DNA fragments were run in an 1% agarose gel and extracted with the 
QIAquick Gel Extraction kit (QIAGEN). Overnight digestion at 37°C with NcoI and KpnI 
(New England BioLabs) followed with: amplified fragment, buffer 1 10× (New England 
BioLabs), 5 U each of KpnI and NcoI and water to a final volume of 30 μl. The digested 
fragments were then run in an 1% agarose gel and extracted.  
Also the destination vector pETM-44 (6-His-MBP tag), provided by EMBL, Heidelberg, 
Germany, was digested with NcoI and KpnI, run in an 0.7% agarose gel and purified in order 
to perform the ligation reaction with the DNA fragment. Ligation was performed overnight at 
16°C. The reaction mix contained: 50 ng of the digested vector, T4 ligase buffer 10× (New 
England BioLabs), 200 U of T4 DNA ligase (New England BioLabs), water to a final volume 
of 10 μl and the digested amplified. The ng of the digested amplified to add was calculated 
according to the empirical relationship: 
 
vectorstedlengthdige
insertstedlengthdigevectordigested
insertdigested

 5     eq.3 
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The ligation solution was used to transform DH5α E. coli cells. Plasmid DNA was then 
extracted using Plasmid Mini lits (QIAGEN) and verified by DNA sequencing by PRIMM 
(Milan, Italy). 
 
 
 
4.2.2 Expression of recombinant proteins in E. Coli  
 
 
pETM-44 vector was used for expression of both constructs. The vector allows the isopropyl 
β-D-1-thiogalactopyranoside- (IPTG-) induced expression in E. Coli strains of proteins . 
BL21(DE3) E. coli strain was used to express the recombinant proteins. Bacterial cells were 
transformed with the pETM-44 constructs and inoculated from a fresh culture (single colony) 
in LB medium added with kanamycin 25 mg/ml. 
The N-terminal tag of the pETM-44 was exploited both to improve the solubility of the 
protein during expression for the presence of the maltose binding protein (MBP), and to 
perform the affinity chromatography on Ni2+-NTA columns (QIAGEN) in the first step of 
the purification, taking the advantage of the 6-His tag. The 6xHis-MBP tag can be easily 
removed by cleavage with HRV-3C protease (Novagen), a commercial recombinant protease 
from human rhinovirus type 14, which recognizes the cleavage site LEVLFQ/GP between the 
tags and the N-terminus of the recombinant proteins (cleavage occurs between the Q and the 
G residue). After HRV-3C proteolysis four residues (Gly-Pro-Met-Ala) remain at the N-
terminus of the constructs.  
Different conditions of induction were tested, varying the temperature of induction and the 
amount of IPTG, in order to find the best condition of expression. The best conditions of 
protein expression are the same for both constructs: 0.5 mM IPTG at 22°C over night. 
 
 
 
4.2.3 Purification of recombinant proteins in E.Coli 
 
 
The same protocol of purification was used for both the constructs, the only difference is that 
PC1 did not undergo to cleavage with HRV 3C protease. 
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After induction, 6×His-MBP-NPHP1 expressing cells were harvested by centrifugation, re 
suspended in 25 ml of lysis buffer + (Table 3) and lysed by sonication. Cell debris were 
removed by centrifugation at 11000 rcf for 45 minutes at 4°C and the supernatant was filtered 
by means of a 0.22 μm filter. The filtered solution was loaded and incubated at 4°C with a 
Ni
2+
-NTA column previously equilibrated with the lysis buffer. After collecting the flow-
through, the column was washed in sequence with 5 volumes of column (CV) of lysis buffer, 
10 CV of wash 2, 10 CV of wash 3 and 5 CV of wash 4 in order to remove proteins that 
bound the Ni
2+-
NTA resin aspecifically (buffer compositions are listed in Table 3). The 
6×His-MBP-tagged recombinant protein was then eluted from the column adding small 
volumes of elution buffer until all the protein was detached from the resin (as checked by 
inspecting small volumes of the eluted solution by adding Bradford reagent). After elution the 
tagged protein was dialyzed over night at 4°C in dialysis buffer (50 mM Tris-HCl pH 7.5, 200 
mM NaCl, 2 mM 2-β-mercaptoethanol), in order to change the buffer and create the best 
possible condition for the cleavage of the protease. To remove the tags, after dialysis, the 
tagged proteins was incubated for 16 hours at 4°C with HRV-3C at ratio 1 unit of enzyme: 0,5 
mg of protein. 
The solution was then loaded onto a Ni
2+
-NTA column previously equilibrated with the 
dialysis buffer in order to remove 6×His-MBP-tags and HRV-3C protease (which also 
presents an N-terminal 6×His-tag). As last purification step, the flow-through was collected, 
concentrated, and loaded onto a HiLoad 16/60 Superdex 75 size exclusion chromatography 
column (GE Healthcare Life Science) equilibrated with a phosphate buffer suitable for 
recording NMR experiments (20 mM NaH2PO4/Na2HPO4 pH 6.3, 150 mM NaCl, 3 mM 
DTT).  
All the purification steps were checked by loading samples of the protein solutions on 15% 
sodium dodecylsulphate polyacrylamide gel eletrophoresis (SDS-PAGE) gels. The amino 
acidic sequences of the both purified recombinant proteins were checked by mass 
spectrometry.  
Uniformly 
15
N- and 
15
N-
13
C- labeled protein samples were obtained by growing and inducing 
the bacteria in M9 minimal medium containing (
15
NH4)Cl without or with 
13
C-glucose, 
respectively (Table 4). Extraction and purification of the labeled proteins were performed as 
previously described. The yield for both unlabeled and labeled NPHP1 1-115 was about 15 
mg/l, whereas the yield of unlabeled CC_PC1 with or without the tag was about 11 mg/l.  
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 Lysis buffer + Lysis buffer - Wash 2 Wash 3 Elution buffer 
Tris-HCl pH 8 20 mM 20 mM 20 mM 20 mM 20 mM 
NaCl 150 mM 150 mM 1 M 150 mM 150 mM 
Imidazole pH 8 10 mM 10 mM 10 mM 30 mM 300 mM 
ZnCl2 100 μM  100 μM  100 μM  100 μM  100 μM  
2-β-mercaptoethanol 2 mM 2 mM 2 mM 2 mM 2 mM 
NP-40 0.2% – – – – 
Complete EDTA-free 
(Roche) 
1 tablet/50 ml – – – – 
Table 3. Buffer compositions for NiNTA purification.  
 
 
 
 15N- labelling 13C- 15N-labelling 
M9 salts pH 7 10× 100 ml 100 ml 
D-glucose 4 g 4 g (
13
C) 
NH4Cl 3g (
15
N) 3g (
15
N) 
Trace elements 1000× 1 ml 1 ml 
CaCl2 1 M 0.3 ml 0.3 ml 
MgSO4 1 M 1 ml 1 ml 
Kanamycin 25 mg/ml 1 ml 1 ml 
Thiamin 1 mg/ml 1 ml 1 ml 
Biotin 1 mg/ml 1 ml 1 ml 
Table 4. Composition of 1 liter of M9 minimal medium for uniformly 15N- and 13C-15N-labelling. 
100 ml M9 salts pH 7 10× contain: 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl; 125 ml traces elements 1000× 
contain: 12.5 g EDTA pH 7.5, 2.10 g FeCl3●6H2O, 210 mg ZnCl2, 30 mg CuCl2●2H2O, 25 mg CoCl2●6H2O, 
25 mg H3BO3, 4 mg MnCl2●6H2O 
 
 
 
4.2.4 Circular Dichroism (CD) experiments  
 
 
CD experiments were recorded on a Jasco J-815 instrument equipped with a Peltier 
temperature control system using a square cuvette with 1 mm path length. Experiments were 
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performed with a sample containing 15 uM of unlabelled NPHP1 1-115 in 20 mM 
NaH2PO4/Na2HPO4 pH6.3, 150 mM NaF, 0,3 mM DTT.  
CD spectra were performed at 293 K. To measure thermal unfolding curves, sample was 
heated at 1°C/min from 283 K to 369 K recording CD signal at two constant wavelengths 
(209 nm and 222 nm).  
Spectra were analyzed using Spectra Manager ® Jasco and secondary structure content was 
estimated using the same program. 
 
 
 
4.2.5 Protein resonances assignment for structure determination  
 
 
Spectral assignment was done using the following spectra: 
1
H-
15
N HSQC, HNCA, HNCACB, 
HN(CO)CACB, HNCO, HNHα, 1H-13C HSQC, CC(CO)NH, HCC(CO)NH, 
(HB)CB(CGCD)HD, HCCH-TOCSY and 
1
H-
1
H TOCSY. In detail the 
1
H-
15
N HSQC, 
HNCA, HNCACB, HN(CO)CACB, HNCO and HNHα spectra were employed to assign the 
backbone, whereas of 
1
H-
13
C HSQC, CC(CO)NH, HCC(CO)NH, (HB)CB(CGCD)HD, 
HCCH-TOCSY and 
1
H-
1
H TOCSY experiments were used to assign the side chains. The 
acquisition parameters are listed in Table 5. 
All NMR spectra were acquired on a Bruker Avance 600 MHz spectrometer equipped with 
inverse triple-resonance cryoprobe and pulsed field gradients, with the exception of  HCCH-
TOCSY acquired on 900 MHz at 298K. Experiments were performed using a concentration of 
protein samples between 0,5 and 0,9 mM in a buffer containing 20 mM NaH2PO4/Na2HPO4 
pH 6.3, 150 mM NaCl, 3 mM dithiotreithol (DTT). D2O percentage was 10% (v/v) or 100% 
(v/v).  
Spectra were processed using NMRPipe
52
and NmrDraw or Topspin NMR software from 
Bruker and then analyzed with CCPNmr software
53
.  
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1
H 
15
N 
13
C  
dim TD SW 
(Hz) 
off 
(ppm) 
TD SW 
(Hz) 
off 
(ppm) 
TD SW 
(Hz) 
off 
(ppm) 
Mx 
(ms) 
1
H-
15
N HSQC D 2048 7211 4.7 200 1824 116.5     
1
H-
13
C HSQC D 2048 6009 4.71    180 21127 72  
1
H-
1
H TOCSY  
(H2O) 
D 2048 7211 4.71       
60 
I 480 7211 4.71       
1
H-
1
H TOCSY  
(D2O) 
D 2048 6602 4.7       
60 
I 480 6602 4.7       
HCCH-TOCSY 
D 1024 10822 4.71    276 9054 65 
12 
I 50 10822 4.71       
HNCA D 2048 8417 4.7 90 1946 118 118 4829 51  
HNCACB D 2048 7212 4.7 80 1825 116.5 162 10563 41  
HN(CO)CACB D 2048 6602 4.7 92 1825 116.5 162 9809 41.5  
HNCO D 2048 8418 4.7 64 1946 118 64 2717 174  
HNHA 
D 1024 6602 4.71 84 1825 116.5    
 
I 160 6602 4.71       
CC(CO)NH D 2048 7212 4.7 70 1825 116.5 170 10865 40 12 
HCC(CO)NH 
D 1024 6602 4.7 56 1307 117.5    
12 
I 204 6602 4.7       
(HB)CB(CGCD)HD D 1024 3597 4.71 200 10564 35     
Table 5: Acquisition parameters of the NMR experiments for NPHP1 1-115 resonance assignment. 
Abbreviations are: “dim”: dimension (“D” and “I” being direct and indirect, respectively), “TD”: time domain, 
SW: spectral width ,“off”: offset ,“m ”: mi ing time.  
 
 
 
4.2.6 Chemical-Shift Rosetta (CS- Rosetta)  
 
 
The chemical shifts are strongly influenced by local conformation, so they represent a helpful 
tool for molecular structure determination by NMR. The secondary chemical shifts (Δδ, the 
differences between the observed chemical shifts and their corresponding random coil values) 
can be used to predict the protein secondary structure
54
. 
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Chemical-Shift Rosetta or CS-Rosetta is a rather innovative program for protein structure 
determination that allows structure determination of protein using only chemical shift 
information. This program combines the well established ROSETTA structure prediction 
program
55
with the empirical relation between chemical shift and structure. 
Rosetta is based on the concept that 3D structure of a protein is directly related to its amino 
acid sequence. Hence for each small segment of the query protein, Rosetta selects two 
hundred fragments from the crystallographic structural database similar for amino acids 
sequence and consequently representative of the possible conformations of the peptide 
segment. Then these fragments are assembled with a Monte Carlo based process to search for 
compact, low energy folds. The refinement protocol of the Rosetta full atoms employs Monte 
Carlo minimization coupled with a detailed all-atom force field in order to search the low 
energy structures. CS-Rosetta improves the Rosetta performance adding the chemical shifts, 
the structural information obtained experimentally
56
. 
 
 
 
4.2.7 Dihedral angles: 3J(HNHα) calculation and TALOS+ prediction  
 
 
3J(HNHα) calculation NMR acquisition.The HNHα is a 3D spectrum in which magnetization 
is transferred from 
1
H and 
15N and then selectively to the backbone 1Hα via three-bonds J-
coupling 3J(HNHα)57. Magnetization is then transferred back via 15N to 1H for detection. 
Hence for each amide group the spectrum displays one diagonal peak and one cross peak, 
corresponding to the resonance of the amide proton and of the α proton of the same residue, 
respectively.  
The e periment is designed to determine accurately the value of the 3J(HNHα) coupling 
constant for each protein residue using the following relation: 
 
 ),32tan2  HJHN
peakdiagonalIntensity
peakcrossIntensity
      eq.4 
 
in which the peaks intensities ratio is a function of the HN-Hα magnetization transfer time (ε) 
and of the 3JHN, Hα value. 
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The value of 3JHN, Hα coupling constants can be converted into the values of the 
corresponding phi dihedral angles of the protein backbone according to the Karplus 
relationship [Eq 5; Figure 16]
57
. The conversion was calculated by means of CCPNmr 
software. 
 
CBAHJHN  )60cos()60(cos,3 2        eq.5 
 
Where the optimal values of the constant A, B and C for the protein are 6.51, -1.76 and 1.60 
respectively. 
 
 
 
Figure 16: The Karplus curve. The 3JHN-Hα is linked to the phi angle.  
 
 
Talos + software. Talos+ is an improved version of the TALOS software (Torsion Angle 
Likelihood Obtained from Shift and sequence similarity), generally used for prediction of the 
dihedral angles phi and psi of a given protein sequence from chemical shifts of 
1Hα, 13Co, 
13Cα, 13Cβ and 15N and 1H of the amide55. 
The protein is divided in the overlapping triplets and only the phi and psi angles of the central 
residue are predicted. An artificial neural network (ANN) analyzes the chemical shifts and the 
sequence and compares this information with a database of 200 protein structures with known 
secondary shifts to obtain a prediction of psi and phi angles and an estimate of the likelihood 
of the prediction depending on the best 10 matches found in the database [Figure 17]. 
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Figure 17: The flowchart of Talos+. (Figure from http://spin.niddk.nih.gov/NMRPipe/talos/). 
 
 
Talos + reports a secondary structure prediction, generated by ANN, and an estimated 
backbone order parameters S2 to prevent assignment of torsion angles to regions that are 
dynamically disordered. In addition, Talos+ prediction can be easily implemented in 
ARIA2.1.3 software to calculate the protein structure using dihedral angles as constrains. 
 
 
 
4.2.8 Determination of NOE restraints  
 
 
The NOE restraints are the most important data for three dimensional structure determination 
of a protein by NMR. They give a range of distances between 
1
H closely atoms (less 5-6 Å). 
They are determined by the intensities of the cross peaks of NOESY spectra, such as 
1
H-
1
H 
NOESY, 
1
H-
15
N NOESY and 
1
H-
13
C NOESY. These interactions drop off very fast with the 
distance as they depend on the inverse of the sixth power of the distance (1/r
6
). Nuclear 
Overhauser Enhancement (NOE) relies on dipolar interactions
58
. 
1
H-
1
H-NOESY (2D) in H2O and D2O, 
1
H-
13
C-HSQC-NOESY for 
13
C aliphatic atoms and 
1
H-
15
N-HSQC-NOESY experiments were performed at 298 K on a Bruker Avance 600 and 
900 MHz spectrometers equipped with inverse triple-resonance cryoprobe and pulsed field 
gradients. Protein samples were 0.7-0.8 mM in NMR buffer. D2O concentration was 10% 
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(v/v) or 100% (v/v). Acquisition parameters are listed in Table 6. NOE cross-peaks were 
manually assigned.  
 
 
 
1
H 
15
N 
13
C  
Dim TD SW 
(Hz) 
Off 
(ppm) 
TD SW 
(Hz) 
Off 
(ppm) 
TD SW 
(Hz) 
Off 
(ppm) 
Mx 
1
H-
1
H-NOESY (H2O) 
D 2048 7212 4.7       
100 
I 480 7212 4.7       
1
H-
1
H-NOESY (D2O) 
D 2048 6602 4.71       
120 
I 480 6602 4.71       
1
H-
13
C-HSQC-NOESY 
(
13
C aliphatic atoms) 
D 2048 10776 4.7    70 18116 40 
100 
I 230 10776 4.7       
1
H-
15
N-HSQC-NOESY 
D 1024 10823 4.7 50 1961 117.5    
100 
I 256 10823 4.7       
Table 6: Acquisition parameters of the NMR experiments for NPHP1 1-115 NOEs assignment. 
Abbreviations are: “dim”: dimension (“D” and “I” being direct and indirect, respectively), “TD”: time domain, 
SW: spectral width, “off”: offset, “m ”: mi ing time.  
 
 
 
4.2.9 Structure calculation  
 
 
The standard procedure to determine the solution structure of a protein from NMR data is to 
minimize an objective function which incorporates experimental data (e.g., intensities of 
assigned NOE cross-peaks, dihedral angles, residual dipolar couplings) and physical 
knowledge (physical and chemical properties of protein nuclei and chemical bonds). The task 
is accomplished by software such as CYANA
59
 and ARIA
60-62
. These programs calculate the 
protein structure based on the conformational restraints using the experimental data and using 
a dynamic force field which describes the protein physical and chemical properties. We used 
ARIA 2.1.3.
62
(see Appendix) to calculate the solution structure of the N- terminus of NPHP1.  
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4.2.10 Dynamic information: 15N spin relaxation measurements  
 
 
NMR spectroscopy is a powerful tool not only to solve the 3D structure of biomolecules but 
also to provide their dynamic information, including their internal motions and the rotation 
diffusion (τc) in solution. The dynamic information of the protein is achieved by means of 15N 
spin relaxation measurement
63
. For this type of investigation three NMR experiments are 
generally acquired: the longitudinal and the transverse relaxation, to obtain T1 and T2 values 
respectively, and of heteronuclearNOE (hetNOE). T1 and hetNOE describe high frequency 
motions, in the time scale of ps-ns, whereas the T2 describes slow motions in the time scale of 
μs-ms. 
All the experiments were performed using 
15
N-labelled NPHP1 1-115 using sensitivity 
enhanced pulse field gradient sequences
64
. Heating effects were minimized combining a 
“dummy” irradiation scheme with an efficient pre-scan 1H saturation sequence65.  
T1 and T2 relaxation delays are listed in Table 7. T1 and T2 values were obtained using the 
fitting routine implemented in NMRView, using the equation 6:  
 
T
t
eII

 0  eq. 6 
 
where I is the peak intensity, I0 is the extrapolation of the peak intensity for null t and T is T1 
(or T2). Both T1 and T2 experiments use a 2.5 seconds recycle delay.  
The HetNOE experiment is based on bidimensional 
1
H -
15
N HSQC experiment.  
In the 
1
H -
15
N HSQC experiment the magnetization is transferred from hydrogen of an amidic 
group to nitrogen directly bound, via J-coupling. Chemical shift is evolved on the nitrogen 
and magnetization is transferred back to hydrogen for detection. Hence in this spectrum all 
amidic groups of the protein are visible (see appendix). 
 
T1 T2 
250* 72 
500 12* 
2000 244 
50* 44 
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900 112* 
1700 28 
150 144 
250 12 
1400 56 
350 112 
50 200 
1100 – 
700 – 
Table 7. List of delays used for the 
15
N relaxation measurements. Delays are expressed in ms. The asterisk 
indicates that the delay has been repeated twice for error estimation.  
 
 
The basic pulse sequence for 
1
H-
15
N HSQC comprises three blocks and then the detection of 
the signal [Figure 18]. Block A comprises a INEPT (Insensitive Nuclei Enhances by 
Polarization Transfer) module, whose purpose is to transfer nuclear spin polarization between 
J-coupled nuclei, from the more sensitive one the hydrogen, to less sensitive one, the nitrogen. 
The time delay Δ/2 is set as near as possible to 1/(4J), where J is the scalar coupling between 
1
H and 
15
N, 
1
JHN value (about 90 Hz). In this manner only magnetization of amide protons is 
transferred to the adjacent 
15
N nucleus. During block B, a 
15
N frequency labeling is achieved 
by incrementing the variable delay t1, which leads to a generation of the indirect dimension of 
the 2D spectrum (F1 frequency). Block C comprises a reverse INEPT module. Nuclear spin 
polarization is again transferred from 
15
N to 
1
H. This enables data acquisition in which 1H 
magnetization is directly detected during t2, which corresponds to F2 frequency in 2D 
spectrum. 
 
 
Figure 18. Basic pulse sequence for 
1
H-
15
N HSQC experiment. 
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HetNOE experiment is performed acquiring two 
1
H-
15
N HSQC in interleaved fashion were 
recorded: one is acquired as a normal HSQC spectrum, used as reference for the intensity of 
the peaks, and the other one is acquired with a presaturation of the 
1
H at the beginning of the 
pulse sequence in order to give rise to the heteronuclear NOE effect between the 
1
H and the 
15
N nuclei [Figure 19].  
 
 
 
Figure 19. Pulse sequence to record 2D 
1
H 
15
N HSQC spectra used to measure the hetNOE for each 
protein residue. 
1
H presaturation is activated at the beginning of 
1
H 
15
N HSQC experiment in which the 
heteronuclear NOE effect works between the 
1
H and 
15
N nuclei. The presaturation is not active in the 
1
H 
15
N 
HSQC reference spectrum . G1, G2 and G3 are gradients. 
 
 
The hetNOE value for each residue is calculated as the ratio of the volume of the HN peak in 
the 
1
H presaturated spectrum (Isat) and the volume of the same HN peak in the reference 
spectrum without 
1
H presaturation (Iref): 
 
Iref
Isat
hetNOE   eq.7 
 
The intensity of the HN peak in the presaturated spectrum depends on the flexibility of the 
residue, the intensity is smaller for residues that belong to flexible regions, in the time scale of 
ps-ns. 
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The value of hetNOE can range between -1 and 1 and it is plotted for each residue of the 
protein in order to visualize the flexible regions and the structured ones of the proteins. The 
structured regions have an hetNOE value between 0.8 and 1 whereas the flexible regions have 
a hetNOE value < 0.5. 
 
 
4.2.11 Residual dipolar couplings (RDC)  
 
 
Residual dipolar couplings (RDCs) measurement allows to investigate internuclear vectors' 
orientations, irrespectively of the distance between them
66
. In order to acquire this 
information for proteins in solution, a partial alignment of the molecules with the field must 
be obtained, leading to an additional coupling to the scalar coupling. 
The 
15
N-
1
H RDC measurements were performed using the axially compressed acrylamide gel 
method described in
67
. A 0.25 ml acrylamide solution (final percentage 5%) was prepared. 
Polymerization was started adding 0.1% w/v ammonium persulfate and 0.5% w/v 
tetramethylethylenediamine (TEMED). Immediately after starting the polymerization, the 
solution was injected into a 3.5 mm plastic tube. As polymerization was completed, the gel 
was removed from the tube, extensively and repeatedly washed with MilliQ water and dried 
overnight at 37°C. The dried gel was then placed into an NMR shigemi sample tube and 0.31 
ml of NMR buffer solution containing 0.3 mM of NSD1-P5C5 was added. After gel had 
absorbed the protein solution and swollen, a vertical pressure was exerted on the plunger to 
reduce its height (which was approximately reduced by a third). A sensitivity enhanced 
HSQC experiment that separates the upfield and downfield components in the indirect 
dimension into different subspectra with a sequence similar to the generalized TROSY 
scheme and decoupling of the N-nucleus during detection 
68
was performed identical protein 
solution in the presence and in the absence of the acrylamide gel. Data were inspected with 
MODULE
69
. The Q factors, which quantify the average agreement between the experimental 
RDCs and the theoretical values calculated from a given structure
70
, have been calculated 
using PALES
71
.  
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4.2.12 NMR titrations  
 
 
The NMR chemical-shift mapping method is a highly sensitive tool to prove binding and to 
map binding sites in protein-ligand interactions
72
. It requires 
15
N-labeled protein in order to 
record 2D 
1
H-
15
N HSQC spectra of the free protein, then stepwise additions of the unlabeled 
titrant are performed and followed by collecting 
1
H-
15
N HSQC spectra after each addition. If 
binding occurs, the chemical environment of the residues that constitute and/or are in close 
proximity to the protein binding site will change. As a consequence, during titration these 
residues show chemical shift perturbations of their backbone amide groups. The type of the 
observed perturbation depends on the rate of binding with respect to the time scale of NMR 
chemical shift: 
 
 if binding is in fast exchange, the exchange between the bound and the free form is faster 
than the difference in chemical shifts. Only one set of protein signals is visible, and their 
positions typically shift according to the ratio between the bound and the free species. 
Therefore, the chemical shifts move from the free form of the protein to the position of the 
bound state, which is reached once the protein sample has been completely saturated with 
ligand. The chemical shift displacement can be fit to a mathematical model and used to 
calculate the affinity (KD) of the interaction.  
 
 If binding is in slow exchange, residues affected show reduction of their peak intensities, 
while new peaks, belonging to the protein in the bound form, appear at different chemical 
shifts, with an increasing intensity upon ligand addition. 
 
 If binding is in intermediate regime, whereby the rate of exchange between the free and the 
bound states is comparable to the difference in chemical shifts between the two states. 
Consequently the behavior is more complicated, as it entails a mixture of signal shifts, 
decreasing signals and newly appearing signals. It results in very broad signals which 
makes the analysis very difficult. 
When the binding is in the fast e change, the HN peaks’ chemical shift displacement is 
measured using the following equation: 
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  eq. 8 
 
The hypothesis that the N-terminus of NPHP1 1-115 domain interacts with the coiled coil 
domain of PC1 (CC_PC1) was tested by NMR titration. The 
1
H- 
15
N HSQC of the free 
15
N N-
terminus of NPHP1 concentrated 0.3 mM was recorded at 298K and then the not labeled 
ligand, the 182 μl of 6His-MBP- CC_PC1 concentrated 0.4 mM, was added and the another 
1
H-
15
N HSQC was recorded. We have tested only the stochiometry 1:1. 
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5. Metabolomics 
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5.1. Metabolomic profiling of the exometabolome of WT and Pkd1 KO cells 
 
 
To find the metabolic hallmarks of Pkd1 KO and WT cells we compared the medium 
conditioned by the presence of cells. We have analyzed the metabolic content of the media 
after one day of conditioning with WT and Pkd1 KO MEF cells, respectively. Importantly 
Pkd1 KO cells display a different phenotype as compared to the WT cells: they show an 
increased cell size, they are double in volume than the WT ones, and they have an increased 
proliferation rate, as shown by the growth curve [Figure 20]. In order to facilitate the 
comparison between the two cell types we decided to perform the metabolomic analysis 
collecting the media after one day conditioning, where both kind of cells have similar number 
of cells and they are in proliferate phase.  
 
 
 
Figure 20. The growth curve of the MEF cells. In orange is shown the curve of growth of Pkd1 KO cells, they 
begin to die starting from the second day of growth, probably because of contact inhibition, in blue is shown the 
curve of growth of WT cells, these cells show proliferation during three days. 
  
 
We next recorded the 1D 
1
H NMR spectra of the media conditioned with the cells, the 
representative spectra of media conditioned with of WT (blue) and Pkd1 KO (orange) cells 
are shown in Figure 21.  
 
 
 58 
 
 
Figure 21. The metabolic profile of the medium conditioned by the presence of Pkd1 KO cells (top), the 
spectrum blue, and the one conditional on the presence of WT cells (bottom) in orange. The numbers 
indicate some assigned metabolites: 1= leucine; 2= valine; 3= isoleucine; 4= ethanol; 5= lactate; 6= alanine; 
7=β-glucose; 8= α-glucose; 9= tyrosine; 10= histidine; 11=formic acid. 
 
 
Using Metabominer
46
, 2D spectra 
1
H-
13
C HSQC and 2D 
1
H-
1
H TOCSY, and CCPN 
Metabolomic project
47
 and the PULCON equation
49
 (see paragraph 4.1.2) we have identified 
and quantified 22 metabolites in the medium (Table 8). The medium conditioned by Pkd1 KO 
cells shows more content of lactate, glutamate and alanine compared to the medium 
conditioned by WT cells, whereas the medium conditioned by WT cells shows more content 
of glucose, glycine, pyruvate, choline and formate [Figure 22 A, B]. 
The Pkd1 KO cells display a metabolism similar to cancer cells producing lactate
9
, 
glutamate
10,11
 and alanine
9
 in the medium. Indeed, similarly to cancer cells, they display an 
accelerated metabolism as indicated by production of lactate, at the same time the production 
of alanine is necessary to secrete the surplus of carbon and nitrogen formed by the fast 
metabolism
9
, whereas the glutamate supplies as stimulus to enhance the cellular growth
10,11
. 
On the other hand the Pkd1 KO cells do not display a major production of glycine as tumor 
cells. The production of glycine could derive from serine degradation, a metabolic pathway 
deregulated in tumors. The secretion of glycine by tumor cells is necessary to protect them 
from the immune response
73
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Metabolite Peak used for 
quantification 
(ppm) 
WT 
 
(mM·10
-6
/cell) 
Pkd1 KO  
 
(mM·10
-6
/cell) 
t-test 
(WT/Pkd1 KO) 
Glucose 
5.24-5.23 (d) alpha 
3.26-3.23 (t) beta 
13.54 (0.20) 6.27 (0.08) *** 
Lactate 4.13-4.10 (q) 5.31 (0.10) 12.80 (0.25) *** 
Pyruvate 2.37 (s) 0.0998 (0.0019) 0.033 (0.0002) *** 
Succinate 2.40 (s) 0.2628 (0.0021) 0.2252 (0.0078) ns 
Choline 3.20 (s) 0.0108 (0.0002) 0.0095 (0.0002) ** 
Formate 8.45 (s) 0.0947 (0.0018) 0.0901 (0.0006) *** 
Ethanol 3.68-3.66 (q) 0.440 (0.003) 0.399 (0.013) ns 
Alanine 1.48-1.47 (d) 0.23 (0.01) 0.279 (0.002) *** 
Arginine 1.67-1.60(m) 0.325 (0.003) 0.251 (0.009) ns 
glutamate 2.36-2.33 (m) 0.132 (0.002) 0.246 (0.007) *** 
Glutamine 2.21-2.06 (m) 1.900 (0.020) 1.800 (0.050) ns 
Glycine 3.56 (s) 0.384 (0.007) 0.277 (0.005) *** 
Histidine 7.09 (s) 0.155 (0.002) 0.122 (0.003) ns 
Isoleucine 
1.01-1.00 (d) 
0.95-0.92 (t) 
0.474 (0.003) 0.358 (0.006) ns 
Leucine 0.97-0.95 (t) 0.386 (0.003) 0.319 (0.012) ns 
Lysine 3.07-3.04 (m) 0.500 (0.002) 0.428 (0.006) ns 
Methionine 2.65-2.63 (t) 0.1018 (0.0005) 0.0902 (0.0012) ns 
Phenylalanine 7.44-7.43-7.41 (m)  0.281 (0.002) 0.225 (0.001) ns 
Threonine 3.59-3.58 (t) 0.700 (0.009) 0.583 (0.004) ns 
Tryptophan 7.74-7.72 (d) 0.064 (0.003) 0.059 (0.002) ns 
Tyrosine 7.20-7.18 (m or d) 0.286 (0.002) 0.220 (0.002) ns 
Valine 
1.04-1.03 (d) 
0.99-0.98 (d) 
0.435 (0.005) 0.348 (0.009) ns 
Table 8. The quantification of the 22 identified metabolites in the medium conditional on the presence of 
Pkd1 KO and the WT MEF cells. In the first column are listed the identified metabolites, the second column 
shows the chemical shifts of the peaks referred to DSS in which s=singlet, d=double, t=triplet, q=quartet ; 
m=multiplet denote the peak multiplicity; α and β indicates the two glucose anomers; the third and fourth 
columns show the quantification of the metabolites identified in the medium conditioned by WT and KO cells, 
respectively, the standard deviation is reported in parenthesis. The last column shows the T-test between KO and 
WT(* p<0.05; ** p <0.001; *** p<0.001). The metabolites in bold are significant in the T-test analysis.  
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Figure 22. The concentrations of the metabolites that result significant forthe T-test analysis. The 
metabolites that present a major amount in the exometabolome conditioned by A. Pkd1 KO cells, and B. WT 
ones. 
 
 
Hence, considering the similarity between the cancer cells and the Pkd1 KO cells, we also 
investigated the concentration of glutamine, another key metabolite of the cancer cells. The 
amount of glutamine in the medium conditioned by Pkd1 KO cells does not display any 
difference compared to the medium conditioned with the WT cells [Figure 23], indicating that 
the metabolism of Pkd1 KO cells share only some similarities with cancer cells. 
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Figure 23. The concentration of glutamine measured in the medium conditioned by Pkd1 KO cells. The 
blue bar, by WT ones, the orange bar and the medium alone, the green one. 
 
 
 
5.2. Pkd1 KO cells display the Warburg effect 
 
 
The concentrations of the 22 metabolites are next used for an unsupervised statistical analysis, 
the principal component analysis (PCA), in order to highlight which metabolites contribute 
mostly to differentiate the two groups of cells [Figure 24]. The score plot displays a well 
defined difference between the two cell lines, showing a separation along the first principal 
component (PC1). The loading plot shows that glucose and lactate contribute mostly to 
separation in PC1. Glucose and lactate are anticorrelated, i.e. Pkd1 KO cells show an 
increased production of lactate in the medium, whereas WT cells show a higher content of 
glucose in the medium. In other words Pkd1 KO cells have a high consumption of glucose 
(decrease of glucose in the medium) and a high production of lactate, as compared to the WT 
ones. 
Among the different metabolites glucose and lactate are the two molecules that mostly 
contribute to the difference between WT and Pkd1 KO cells [Figure 24].  
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Figure 24. PCA analysis. On the left the score plot: the Pkd1 KO and the WT cells are very well separated by 
the first component (PC1); on the right the loading plot: glucose and lactate contribute to the separation between 
the two cell lines in opposite manner. 
 
 
From this result we have hypothesized that the Pkd1 KO cells are affected by the aerobic 
glycolysis, the so called Warburg effect, the metabolic hallmark of cancer cells
74
. We 
hypothesize that the aerobic glycolysis derives from the loss of functional PC1. As the C- tail 
of PC1 regulates negatively mTORC1
41
 it is conceivable that the loss of functional PC1 leads 
to an enhanced activity of mTORC1 that has as metabolic effect on the aerobic glycolysis. As 
the analyzed MEF cells derive from two different mice, we cannot exclude a priori that the 
observed metabolic change might to be attribute to a clone-to-clone variation effect, to 
exclude this possibility we have performed and analyzed the 1D 
1
H NMR spectra on the 
medium conditioned by MEF cells isolated from a mouse model carrying Floxable alleles of 
the Pkd1 gene. MEF cell lines (Pkd1
flox/flox
) were isolated and immortalized. To achieve the 
inactivation of the Pkd1 alleles without introducing clonal effects due to genomic integration 
of the Cre gene, a cell-permeable TATCre fusion protein capable of efficiently inducing the 
recombination of loxP sites and that is subsequently degraded by the cells
41
 were used. 
Treatment with the Cre recombinase resulting in a minimum of 70 to 80% inactivation of the 
Pkd1 allele, as assessed by PCR analysis of the genomic DNA. The resulting Pkd1
flox/flox
 MEF 
population is not affected by clone-to-clone variability, but, at the same time, it is not totally 
knock-out for Pkd1 gene. 
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In order to evaluate the consumption of glucose in the medium conditioned with the different 
cell types we have expressed the amount of glucose as consumption using the following 
equation: 
 
   
cellsofnumberfinal
cellsremainingeglumediumeglu
nConsumptio
coscos 
  eq.9 
 
We have calculated the glucose consumption and the lactate production also for the Pkd1 KO 
, WT MEF cells, and Pkd1 
flox/flox  
MEF cells [Figure 25 A, B]. 
Taken together all these experiments clearly indicate that the Warburg effect is due to the loss 
of PC1. 
 
 
 
Figure 25. Glucose consumption and lactate production. A Pkd1 KO and WT MEF cells and B Pkd1
flox/flox 
MEF cells. 
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5.3. Additional experiments in support of metabolic dysfunction in Pkd1 
KO cells  
 
 
The metabolomic analysis on the different cellular models reveals that the loss of PC1 leads 
to the aerobic glycolysis as Pkd1 KO MEF cells show a major consumption of glucose and 
major production of lactate. To support these data and to study the molecular mechanism 
associated to the loss of PC1, our collaborators have performed additional experiments, that 
have been briefly summarized in the following. 
 
 
5.3.1 Demonstration of Warburg effect 
 
 
As expected the Pkd1 KO MEF cells display more ATP content compared to the WT ones 
[Figure 26 A]. Treating cells with oligomycin, a drug able to block the ATP-synthase and 
hence the production of ATP through oxidative phosphorylation, the intracellular amount of 
ATP decreases in both cell lines, but importantly the difference in ATP content between the 
Pkd1 KO and WT cells is not restored [Figure 26 B]. This result confirms that the Pkd1 KO 
cells are affected by Warburg effect. 
 
 
 
Figure 26. The quantification of the amount of ATP. A. The amount of ATP measured 24, 48 and 72 hours 
respectively after cellular plating. B. The amount of ATP measured in the absence or in presence of oligomycin, 
respectively. Results deriving from Pkd1 KO and WT cells are shown in white and black bars, respectively. 
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Moreover, real-time PCR analysis reveals that Pkd1 KO cells display a transcriptional 
signature of glycolytic enzymes [Figure 27], showing an increase of the transcript of lactate 
dehydrogenase A (LDHA) and pyruvate kinase M2 (PKM2). Whereas the transcript of the 
hexokinase I (HKI), that phosphorylates the glucose, does not display a significant difference. 
 
 
 
Figure 27. The transcription signature of Pkd1 KO (white bar) and WT (black bar) cells. 
 
 
In addition AMPK is, at the same time, inhibited [Figure 28 A]  in Pkd1 KO cells by the 
major intracellular content of ATP and by LKB1
75
, that is regulated by ERKs pathway 
[Figure 28 B]. 
 
 
 
Figure 28. AMPK is inhibited by the loss of functional PC1. A. The Pkd1 KO cells show a decrease of 
phosphorylation of AMPK and a related increase of the phosphorylation of ERK. B. The increase of 
phosphorylated LKB1 in Pkd1 KO cells. 
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5.3.2 Proliferation and apoptosis in Pkd1 KO cells depend on glucose metabolism  
 
 
Pkd1 KO cells present an increased proliferation and apoptosis
76,77
 which are dependent on 
mTORC1
41
 and on glucose metabolism. Indeed glucose deprivation reduces proliferation 
[Figure 29 A] and sensitizes Pkd1 KO cells to apoptosis [Figure 29 B]. 
 
 
 
Figure 29. The role of glucose starvation in A. proliferation rate measured using Ki-67 protein as marker and 
B. in the activation of autophagy. S6RP is the S6 ribosomal protein, a downstream target of mTOR pathway, its 
major phosphorylation indicates an increased activity of mTOR. LC3 is a marker of autophagy and in particular 
the amount of LC3 II correlates well with the number of autophagosomes and it is used to monitor the 
autophagic activity of the cells. 
 
 
 
5.4. Treatment with drugs  
 
 
5.4.1 Exometabolome of MEF cells treated with drugs 
 
 
The up regulation of ERK pathway due to the loss of PC1 in Pkd1 KO cells leads to an 
enhanced activity of mTORC1 that induces the aerobic glycolysis and a production of ATP 
that inhibits AMPK. On the other hand the up regulation of ERK pathway phosphorylates 
LKB1, activating it and consequently inhibiting AMPK. 
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Each step of this proposed signaling cascade can be targeted by a drug, approved by FDA. For 
example AMPK is activated by metformin
78
 and AICAR
79
, mTORC1 activity is inhibited by 
rapamycin
42
 [Figure 30]. 
 
 
 
Figure 30. The scheme of the proposed signaling cascade associated to the loss of PC1. In Figure are 
highlighted the tested drugs and their relative targets. 
 
 
To investigate the effects of each drug on the glucose metabolism, different experiments have 
been performed. MEF cells were treated for 48 hours with rapamycin, AICAR and metformin, 
singularly. The medium is then collected to perform 1D 
1
H NMR experiments and then we 
have quantified and compared the consumption of glucose [Figure 31 A] and the production 
of lactate [Figure 31 B] for Pkd1 KO and WT cells not treated or treated with each drug 
singularly. The amount of glucose consumption and lactate production of WT cells does not 
display any changes upon treatment with different drugs. The Pkd1 KO cells do not revert 
their metabolic phenotype after drug treatment as they maintain an increase of glucose 
consumption and lactate production. This effect is emphasized principally by treatment with 
metformin, as expected because the lactic acidosis is one of the side effect of the metformin
78
. 
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Figure 31. Comparison between not treated and treated Pkd1 KO and WT MEF cells. A. Glucose 
consumption and B. the lactate production of WT (orange) and Pkd1 KO cells (blue) in different condition: 
starting from left, not treated, treated with rapamycin (rapa), with metformin (met) and treated with AICAR. 
 
 
Also cells treated with AICAR display the same phenotype of the cells treated with 
metformin, even though lactic acidosis is not known as side effect of the treatment with 
AICAR. Overall the treatment with AICAR results very toxic for cells indeed they show an 
high death rate. 
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5.4.2 Additional experiments to test the effects of the drugs on the signaling cascade 
and the related biological effects. 
 
 
The treatment with AICAR, metformin or rapamycin is not able to revert the metabolic 
phenotype of the Pkd1 KO cells. Our collaborators have therefore performed additional 
experiments in vitro in order to verify the effect of these drugs on the signaling cascade and to 
the related biological effect. 
Treating Pkd1 KO cells with rapamycin the autophagy [Figure 32 A] and cell survival under 
glucose deprivation are partially restored [Figure 32 B]. 
 
 
 
Figure 32. Effect of the treatment with rapamycin.A. Rapamycin partially restores the autophagy in Pkd1 KO 
cells (white bar) B. Rapamycin decreases the apoptotic level of Pkd1 KO cells under glucose starvation 
conditions. 
 
 
Treatment with metformin and AICAR [Figure 33 A, B] activates AMPK and, unexpectedly, 
inhibits ERKs pathway.  
These data suggest the existence of a negative feed-back whereby AMPK can regulate ERKs 
activity. Thus, the signaling cascade related to the loss of PC1 is possibly regulated in a 
circular manner suggesting that acting at any level of the cascade might restore the basal 
condition [Figure 34]. 
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Figure 33. Effect of the treatment with metformin and AICAR. A. The effect of metformin and B. AICAR 
on AMPK and the ERKs pathway. 
 
 
 
Figure 34. A proposed model of signaling cascade due to the loss of PC1. 
 
 
5.5. In vivo experiments  
 
 
In order to verify that the Warburg effect occurs also in vivo we have performed NMR 
experiments on the polar extract of the whole kidney deriving from of Ksp-Cre: Pkd1
flox/- 
and 
Pkd1
flox/+ 
mouse model
12
 in which PC1 is inactivated only in kidneys. 
The Pkd1
flox/-
 KO kidneys and the Pkd1
flox/+ 
WT kidneys are quite different: the KO kidney is 
bigger than the WT one and it weights about ten times (340 mg) more than the WT one (34 
mg) [Figure 35 A]. After lyophilization the weight of the KO kidney decreases of about ten 
 71 
 
times, whereas the weight of the WT kidneys decreases of about three fold compared to the 
weight of the corresponding fresh tissue [Figure 35 B], highlighting that the increase of renal 
weight is due to the fluid contained in the cysts. The lyophilized KO kidney is more fragile as 
compared to the WT one because of the loss of the renal architecture. 
 
 
 
Figure 35. The mouse kidneys A before lyophilization and B. after lyophilization. We can appreciate that the 
KO kidney Pkd1flox/- , the left one in both pictures, is bigger than the WT kidney Pkd1flox/+, on the right. 
 
 
 
5.5.1 1D 1H NMR experiments of polar extracts deriving from lyophilized kidneys  
 
 
We have analyzed the polar metabolites extracted from three WT and three KO kidneys 
deriving from three different litters. We have performed 1D 
1
H NMR experiments [Figure 36] 
and analyzed the content of glucose and lactate.  
The amount of these two metabolites is expressed as the ratio integral/dry weight to account 
for the difference in weight of the two kidneys. The KO kidneys show more glucose [Figure 
37 A] as compared to the WT. However the measured lactate content [Figure 37 B] is affected 
by a high error. Because of these high errors this experiment was judged insufficient to 
confirm that the Warburg effect occurs also in vivo. From these experiments we can only 
hypothesize that the KO kidneys have more glucose content than WT ones.  
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Figure 36. The representative kidney 1D 
1
H NMR spectra. Pkd1
flox/+
 WT kidney (top) and Pkd1
flox/- 
KO 
kidney (bottom). 
 
 
 
 
 
Figure 37. The amount of A. glucose and B. lactate in kidneys. The blue bar represents the KO kidneys and 
the orange one the WT ones. 
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5.5.2 13C glucose experiments  
 
 
The analysis of the 1D 
1
H NMR spectra acquired on the polar extracts of the whole kidney 
does not confirm the Warburg effect in vivo. The high error that affects the measurements is 
probably related to the genetic variability between the litters. Hence, following a protocol 
previously reported in literature
13,14
 we have decided to perform experiments using uniformly 
labeled 
13
C glucose in order to follow the path of glucose and its conversion into lactate. We 
have performed a preliminary kinetic experiment in order to set the best experimental 
conditions, including: the amount of glucose to inject, the time point in which to sacrifice the 
mouse, the type of spectra to acquire and how to analyze the data. In order to follow the 
glucose pathway and its conversion into lactate we have collected and analyzed serum, urine, 
kidneys and liver, as control organ.  
We have first tried to acquire the 1D 
13
C spectra [Figure 38]. Unfortunately, the 1D 
13
C 
spectra could not be used because the glucose and lactate signals of the WT kidneys were 
comparable to the noise signal, their intensities were affected by big errors and could not be 
used for quantification [Figure 38 top]. To increase sensitivity we have acquired 
1
H 
13
C 
HSQC on the same samples and we have used the corresponding peaks to analyze the glucose 
and lactate content. 
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Figure 38: Representative kidney 1D 
13
C spectra. WT (top) and KO (bottom) of 1D 
13
C kidney spectrum 
collected after 40 minutes from 
13
C glucose injection.  
 
 
Kinetic experiments. For choosing the time point in which to sacrifice the mice, we have 
performed a kinetic experiment following the amount of 
13
C glucose and 
13
C lactate in serum, 
urine, livers (organ control) and kidneys at three different time points. 
We used a litter composed by 8 littermates: 4 KO and 4 WT mice. Mice were sacrificed after 
20, 40 and 60 minutes after 
13
C-glucose injection (after 40 minutes 2 mice were sacrificed to 
have a replicate of this time point). 
We have acquired 
13
C-
1
H HSQC experiments on serum, urines, kidneys and livers and we 
have measured the concentration of glucose and lactate (see paragraph 4.1.4). 
Lactate was not present in urine and serum, therefore in biofluids we could only detect the 
glucose amount [Figure 39]. The urine deriving from KO mice are more diluted as compared 
to WT urines because of the loss of renal function, consistently the amount of glucose is very 
small as compared to WT. Monitoring the decrease of the amount of glucose in the 
bloodstream during the time we can appreciate that the KO mice have a quicker glucose 
consumption as compared to the WT ones. This effect could be an indication of the 
accelerated metabolism that affects the KO mice.  
In kidneys and livers we have detected both glucose and lactate. The KO organs show more 
glucose and lactate and the difference is more relevant 40 minutes after 
13
C glucose injection. 
In detail, the difference in the content of glucose and lactate is significant in the kidneys but 
not in livers [Figure 40 A and B].  
 75 
 
Hence we have decided to perform the following experiments sacrificing the mice 40 minutes 
after 
13
C glucose injection. 
 
 
 
Figure 39. Glucose quantification. The concentration of glucose in urine (on the left) and in serum (on the 
right). 
 
 
 
Figure 40. Glucose and lactate quantification. The measured concentration of glucose and lactate in A. 
kidneys and B. liver.  
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13
C glucose experiments after 40 minutes from glucose injection. Based on the kinetic 
experiments we have decided to perform all the following experiments only on the kidneys 
and livers collected after 40 minutes from glucose injection. 
To remove the differences due to the genetic variability between the five litters used for the 
experiments and to appreciate only the difference due to the loss of PC1, the WT of each litter 
was used as internal standard, expressing the amount of glucose and lactate of the KO kidney 
as ratio with the corresponding amount of WT kidney (R=IKO/IWT).  Next,  we have calculated 
the average and the standard deviation both for kidneys and for livers (see paragraph 4.1.4).  
Analyzing the 
1
H 
13
C HSQC spectra performed on the polar extracts of the kidneys we have 
confirmed that the Warburg effect occurs also in vivo and it is caused by the loss of PC1. 
Indeed the Pkd1 KO kidneys contain more glucose [Figure 41 A] and lactate [Figure 41 B) 
than the WT ones, whereas the Pkd1 KO livers do not show significant differences in glucose 
and lactate content.  
 
 
 
Figure 41. Glucose and Lactate quantification A. The amount of glucose in kidneys on the right and liver on 
the left. B. The lactate content in kidneys on the right and liver on the left. In orange the ratio between the WT 
organs and in blue the ratio between KO and WT organs. 
 
 
To support these data our collaborators have measured the renal ATP content [Figure 42 A] 
confirming that KO kidneys have more ATP than the WT ones, and through the real time 
PCR analysis they have confirmed that the up regulation of glycolytic enzymes occurs also in 
kidneys showing an increase of the transcripts of hexokinase I (HK I) and pyruvate kinase 
(PMK2), whereas the transcript of the lactate dehydrogenase A (LDHA) does not display a 
significant difference [Figure 42 B]. 
 77 
 
 
 
 
Figure 42. The Warburg effect occurs also in vivo. A. The ATP content in kidneys. B. The real time PCR 
analysis on the glycolytic enzymes. 
 
 
 
Through Western blot analysis [Figure 43] they have also verified that the up regulation of 
ERKs pathway occur also in kidneys with the related enhanced activity of mTORC1 and the 
inhibited activity of AMPK, as previously demonstrated in the cellular model [Figure 34]. 
 
 
 
Figure 43. The proposed signaling cascade occurs also in vivo. Western blot analysis confirms that the 
hypothetic pathway discovered in cellular model occurs in vivo. 
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5.6. Treatment with 2-deoxy glucose (2DG)  
 
 
Through 
13
C glucose NMR experiments we have demonstrated that the Warburg effect and 
the related signaling cascade associated to the loss of PC1 also occurs in vivo. 
We next wondered whether it was possible to block the Warburg effect blocking glucose 
metabolism using 2-deoxy-glucose (2DG). 
2DG is a drug able to block the glucose metabolism being an analog of the glucose that 
cannot be metabolized [Figure 44 A]. It is a competitor of the glucose and it is phosphorylated 
by the hexokinase 1 but it is not metabolized by the next enzyme involved in the metabolism 
of glucose, for example the phosphoglucose isomerase for glycolysis, and the glucose 6-
phosphate dehydrogenase for the pentose phosphate pathway [Figure 46 B]. Generally, cells 
treated with 2-DG increase the number of glucose transporters on the cellular membrane in 
order to enhance the uptake of glucose to survive
15,16
. The treatment leads to an increase in the 
intracellular glucose content and a decrease of the metabolic products of glucose In order to 
observe changes in the glucose metabolism upon treatment with 2DG we have analyzed the 
polar extracts of kidneys and livers deriving from three different litters treated at the same 
time with 2-deoxy-glucose (2DG) and uniformly labeled 
13
C glucose performing the 
1
H 
13
C 
HSQC NMR experiments. 
In order to check the efficacy of the treatment independently from the genetic variability we 
have used the untreated Pkd1 KO organs as internal standard (R2DG= IKO_2DG/IKO) (see 
paragraph 4.1.4). Notably the treatment with 2DG is effective only in kidneys and not in the 
liver (control organ). 2DG does not affect the glucose content but only the lactate content that 
decreases in kidneys whereas the livers does not appear to be affected by the treatment 
[Figure 45 A and B].  
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Figure 44. Structure and metabolism of 2DG. A. Structure comparison of glucose and 2-deoxy- glucose. 2DG 
and glucose differ in the second carbon. B. Schematic representation of 2-DG action. 2DG enters in the cell 
through the glucose transporter and it is phosphorylated by hexokinase. Due to low levels of intracellular 
phosphatase, 2-DG-PO4 is trapped inside the cell. 2-DG-PO4 is unable to undergo further metabolism. High 
intracellular levels of 2-DG-PO4 cause allosteric and competitive inhibition of hexokinase. This results in 
inhibition of glucose metabolism. [Figure from Aft RL et al. British Journal of Cancer, 2002]. 
 
 
 
 
 
Figure 45. Quantification of glucose and lactate. A. The glucose content for kidneys, on the right and liver, on 
the left. B. the lactate content for kidneys and liver. In blue the ratio between the KO organs not treated with 
2DG, in violet the ratio between the KO not treated organs with the KO organs treated with 2DG. 
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In addition our collaborators have highlighted that the treatment with 2DG improves the 
histology of the kidneys, as they present a decrease in cystic volume in the weight of the 
organ [Figure 46 A] and in the index of proliferation of cystic lining epithelium [Figure 46 B]. 
 
 
 
Figure 46. Effect of 2DG treatment on the renal histology. A. The histology of KO kidneys not treated (top) 
and treated with 2DG (bottom). B. The measure of the proliferation index. 
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6. Structure of the N-terminus of 
NPHP1 
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6.1 The recombinant N-terminus of NPHP1 is soluble. 
 
 
To study the putative coiled coil domain of the human NPHP1 (spanning the first 115 amino 
acids of the NPHP1) the corresponding DNA sequence was cloned into pETM44 and the 
recombinant domain was expressed in E. Coli and purified as described in paragraph 5.1. The 
construct has the following sequence, where the amino acids belonging to the tag and that 
remain after the protease cleavage are highlighted in italics: 
 
GPMAMLARRQRDPLQALRRRNQELKQQVDSLLSESQLKEALEPNKRQHIYQRCIQLK
QAIDENKNALQKLSKADESAPVANYNQRKEEEHTLLDKLTQQLQGLAVTISRENITEV
GAPT 
 
The recombinant protein was soluble and folded, as shown by the good peak dispersion of the 
1D and 2D NMR spectra [Figure 47] moreover the sharp peaks of 1D NMR spectrum showed 
that the protein was also monomeric.  
 
 
 
Figure 47. NMR spectra of the putative coiled coil domain of NPHP1. A. The 1D 
1
H NMR spectrum and B. 
the 2D 
1
H-
15
N HSQC of the putative coiled coil domain of NPHP1 concentrated 0.4 mM, recorded at 298K in 
PBS 20mM, 3mM DTT. 
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6.2 The N-terminus of NPHP1 is predicted to be a coiled coil domain 
 
 
The first 115 amino acids (13kDa) of NPHP1 were predicted to be a coiled domain by the 
Web Server PCOIL [Figure 48]. The coiled coil domain is a structural motif in which two or 
more alpha helices are coiled together. It is characterized by the repetition (3-4 times) of 7 
amino acids, whose positions are defined as a, b, c, d, e, f, g. In particular, position a and d are 
occupied by hydrophobic amino acids, e and g by charged amino acids, these positions are 
important for structure stabilization
18
. This kind of domain is usually involved in protein-
protein interaction
18,24,25,80
. In particular COILS predicts for  the N-terminus of NPHP1 the 
presence of a coiled coil from residues Leu 14-Glu 34; Ile 54-Glu75 and Asn 83-Ala 104. 
Surprisingly, the recombinant protein does not show any sign of aggregation and dimerization 
as assessed form gel filtration elution volume, which corresponds to the volume associated to 
a protein of 13kDa. Moreover 1D NMR 11-echo experiments indicate that the overall 
correlation time of the protein is 15 ms, which is in line with a molecular weight of 13 kDa , 
being in monomeric for in solution. 
 
 
 
Figure 48. COILS web server prediction. COILS compares the sequence with a database of known coiled 
coils and derives a similarity score. Then the program calculates the probability that the sequence will adopt a 
coiled coil conformation. The graph show the coiled coil probability over the sequence. COILS uses sliding 
windows of 28 (red), 21 (blue) and 14 (green) amino acids. The most accurate prediction is for window of 21 
amino acids. 
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6.3 The N-terminus of NPHP1 is thermostable and contains α-helices 
 
 
We have performed circular dichroism (CD) experiments on the N-terminus of NPHP1 
(NPHP11-115) in order to characterize the secondary structure of this domain and its thermal 
stability.  
The CD is a very useful technique to study the protein folding and to characterize its 
secondary structure, to determine whether protein-protein or protein-ligand interactions alter 
the conformation of protein and to investigate the conformational stability of a protein in 
denaturing conditions (such as temperature, pH and denaturants).  This technique is based on 
the measurement of the differences in the absorption of left-handed polarized light versus 
right-handed polarized light which arises from structural asymmetry in the "far-UV" spectral 
region (190-250 nm). At these wavelengths the chromophore is the peptide bond, and the 
signal arises when it is located in a regular, folded environment. Alpha-helix, beta-sheet, and 
random coil structures each give rise to a characteristic shape and magnitude of CD spectrum. 
The CD spectrum of the N-terminus of NPHP1 shows a typical α heli  profile [Figure 49] 
with two minima at 209 nm and 222 nm and a maximum at 192 nm. 
 
 
 
Figure 49. The CD spectrum of the N-terminus of NPHP1. CD experiment was performed using 20μM of 
protein in solution with 20mM phosphate buffer, 150 mM NaF and 0.3 mM DTT. 
 
 
 
This domain contains ~ 45% of α heli , as estimated from the molar residual ellipticities value 
at 209 nm and 222 nm ( -14000 deg mol
-1 
cm 
-2
) using the following equation
81
: 
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   39000/3000% 222  nmalphahelix        eq.10 
 
Finally, the melting curve obtained following the changes of the molar ellipticities value at 
209 nm shows that the domain is extremely stable with a high melting temperature of ~ 65°C 
[Figure 50]. 
 
 
 
Figure 50. The melting curve of the putative coiled coil domain of  NPHP1. CD experiment was performed 
using 20μM of protein in solution with 20mM phosphate buffer, 150 mM NaF and 0.3 mM DTT. 
 
 
 
Taken together these results show that the N-terminal domain of NPHP1 has a high α helical 
content, as secondary structure, and it is thermostable. 
 
 
 
6.4. NMR experiments 
 
 
We have solved the structure of NPHP11-115 using classical multidimensional- heteronuclear 
NMR experiments (see paragraph 4.2.5) 
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6.4.1 NPHP11-115 chemical shift assignment.  
 
 
1
H, 
15
N and 
13
C resonances of the NPHP11-115 were assigned through 2D and 3D homo- and 
heteronuclear experiments (as described in paragraph 4.2.5 and appendix). We started with 
the peak picking of the 
1
H-
15
N HSQC spectrum and analyzing the HN strips in the 3D HNCA, 
HNCACB and HN(CO)CBCA in order to assign the backbone resonances [Figure 51]. 
 
 
 
Figure 51. Representative strips showing backbone assignment. Amide strips of HNCA NMR spectrum for 
Gln 68, Lys 69 and Leu 70 used to assigned the chemical resonance of the 
13
Cα. The amide nitrogen is coupled 
both to the Cα of its own residue and to the Cα of the preceding residue, both these magnetization transfers occur 
and peaks for both Cα nuclei are visible in the spectrum. However the coupling to the directly bonded Cα is 
stronger, hence the corresponding peaks will appear with stronger intensity. 
 
 
Because of the high α-helical content peaks clustered in the central part of the HSQC 
experiments making the assignment procedure quite difficult because of peaks overlap. 
Despite these difficulties we have assigned   98.3 % of the backbone,   98% of the 1H side 
chain and   9% of the NH groups belonging to the side chains. We used backbone chemical 
shifts to obtain the Chemical Shift Index (CSI) plot of the construct [Figure 52]. The CSI 
procedure allows to compare the 
1Hα, 13Cα, 13Cβ and 13CO chemical shifts of the protein 
residues  with 
1Hα, 13Cα, 13Cβ and 13CO chemical shift of the same residues in random coil 
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conformation. The comparison allows to assign a value (named chemical shift index) ranging 
from -1 to 1, representing the propensity of each residue to be in α-heli  or in β-strand, 
respectively.  
 
 
 
Figure 52. The CSI plot made by means of CCPNmr. The chart confirm that the domain shows only α helices 
as secondary structure. 
 
 
In agreement with circular dichroism spectra, the CSI confirms that the N- terminus of 
NPHP1 contains only α-helices as elements of secondary structure, in detail the first helix 
spans residues Leu 14 and Glu 36 residues, the second one Asn 44 – Lys 69 and the third one 
Asn 83 – Thr 108. 
 
 
6.4.2 3D structural model obtained with CS Rosetta 
 
 
In order to obtain a structural model of the NPHP11-115 we have used Chemical-Shift Rosetta 
(CS-Rosetta), an innovative software for protein structure determination that allows structure 
determination of protein using only chemical shift information
55
. 
The model of the first 115 amino acids of the human NPHP1 shows, as e pected, only α 
helices as secondary structures. The domain is composed by three helices: the first between 
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the  Pro13 to the Gln 36, the second from Pro 43 to Asn 69 and the third between Tyr 82 to 
Asn 111, connected by short loop, almost completely in agreement with the result obtained 
with the CSI. 
 
 
 
Figure 53. The 3D model of NPHP11-119 obtained with CS-Rosetta. The NPHP11-115 displays a helix bundle 
fold. 
 
 
 
6.4.3. Hydrogen–deuterium exchange 
 
 
To identify the backbone amide protons involved in hydrogen bonds the 
15
N labeled sample 
was lyophilized and re-suspended in 100% of D2O.  A series of 
1
H-
15
N HSQC were recorded 
at different time after the re-suspension in D2O. The amide hydrogens exposed at the solvent 
exchange with deuterons very fast becoming invisible in the spectrum in a short time after re-
suspension with D2O, whereas the hydrogen atoms involved in H-bonds exchange more 
slowly with deuterons, remaining visible in the spectrum after long time after the re-
suspension in D2O. 
After one hour from the re-suspension in D2O in the 
1
H-
15
N HSQC [Figure 54] 21 HN are still 
visible. They belong to the following residues: Leu 24, Gln 26, Gln 27, Val 28, Asp 29, Leu 
31, Leu 32, Ile 54, Leu 56, Lys 57, Gln 58, Ala 59, Asp 61, Glu 62, Asn 63, Lys 64, Leu 96, 
Thr 97, Leu 100 and Leu 101.  
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These residues, which are more protected from solvent exchange, are presumably involved in 
the formation of hydrogen bonds forming the α helix. This information will be used as 
restraint in the structure calculation.  
 
 
 
Figure 54. The 
1
H-
15
N HSQC recorded after 1 hour from re-suspension in D2O. 21 amide HN are still 
visible in the spectrum and represent the NH groups involved in the H-bonds. 
 
 
 
Figure 55. The amino acids involved in H-bonds. A. The residues that do not exchange with D2O are 
highlighted in the 3D structure. In red the residues belonging to the first helix, in blue to the second one and in 
magenta to the third. B. An example of H-bond formed in the structure. The H-bond takes place between the 
amide -HN group of the Ile 54 and the –C=O of the Tyr 50. 
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6.4.4 Experimentally calculated phi angle and Talos + prediction 
 
 
The 3D HNHα e periment correlates the 1HN and 
15
N atoms of a residue to its 
1Hα atom. This 
spectrum is useful to extract the 
3J(HNHα) coupling constants from the ratio of the volume of 
the cross peak (
1
HN-
1Hα) with the corresponding diagonal peak (1HN-
1
HN). The Karplus 
equation (paragraph 4.2.7, equation 5) correlates  the phi angle of each residue with the 
corresponding 
3J(HNHα) (see paragraph 4.2.7). The values of 3J(HNHα) can therefore give 
information on the local backbone conformations of the single residues: 
3J(HNHα) values < 
4.8 Hz and values >8.5 Hz indicate that the corresponding residue adopt an  α-helical and 
conformation β strand conformation, respectively. The 3J(HNHα) value could not be 
calculated for each residues because some HN strips contained superimposed peaks belonging 
to different 
1
HN due to the similarity of 
1
HN chemical shifts because of the high level of 
overlapping signals. Overall we obtained only 38 reliable 
3J(HNHα) values. 
In addition we have also employed the software Talos + (see paragraph 4.2.7) in order to 
estimate the phi dihedral angle from the 
1
Hα, 
13C’, 13Cα, 
13
Cβ and the amide 
15
N and 
1
H 
chemical shifts. The software was able to make a good estimate for 93 residues (78%). The 
predicted and the calculated phi angles are listed in table 9. 
 
  
 Talos + HNHα   Talos + HNHα 
 Phi Δphi Q 3J E Phi   Phi Δphi Q 3J E Phi 
Ala 4 -92.8 80.7 dyn - - -  Ile60 -60.8 6.16 good - - - 
Met 5 -85.0 76.2 dyn - - -  Asp61 -62.7 4.15 good - - - 
Leu 6 -101 28.8 dyn 6.64 0.039 -161,-79  Glu62 -66.6 4.24 good - - - 
Ala 7 -89.9 25 dyn - - -  Asn63 -64.7 4.98 good - - - 
Arg8 -88.5 30.2 dyn - - -  Lys64 -62 5.32 good 4.23 0.64 -61 
Arg 9 -110 63.9 dyn - - -  Asp65 -61.3 7.85 good - - - 
Gln 10 -108 64.3 dyn - - -  Ala66 -69.2 6.25 good 4.3 0.52 -62 
Arg 11 -94.4 90.9 dyn - - -  Leu67 -64.7 9.85 good - - - 
Asp 12 -80.9 28.8 good - - -  Gln68 -67.3 7.92 good 4.44 0.42 -177,-63 
Pro 13 -62.8 8.9 good - - -  Lys69 -93.9 17.33 good 7.37 0.27 -155,-85 
Leu 14 -65.6 2.97 good - - -  Leu70 -76.9 54.82 warn 4.78 0.48 -175,-65 
Gln 15 -64.3 4.72 good - - -  Ser71 -92.3 27.42 good - - - 
Ala 16 -67.8 5.94 good - - -  Lys72 -64 4.71 good 5.8 1.5 -73 
Leu 17 -67 4.77 good - - -  Ala73 -69.5 8.82 good 4.95 0.3 -173,-67 
Arg 18 -62.7 4.45 good 3.07 1.06 -51  Asp74 -68.6 9.26 good - - - 
Arg 19 -66.8 6.03 good - - -  Glu75 -68.4 10.22 good - - - 
Arg 20 -66.1 5.57 good - - -  Ser76 -95.4 21.81 good - - - 
Asn 21 -65.9 6.76 good 3.67 0.83 -56  Ala77 -81.1 22.64 good 5.8 0.16 -167,-73 
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Gln 22 -65.8 6.05 good - - -  Pro78 -62.7 7.61 good - - - 
Glu 23 -66.6 6.03 good - - -  Val79 -101.6 19.42 good - - - 
Leu 24 -67.6 5.38 good - - -  Ala80 -67.3 12.28 warn 3.9 0.46 -59 
Lys 25 -61.4 4.13 good - - -  Asn81 -83.4 22.57 good 7.3 0.51 -156,-84 
Gln 26 -61.7 3.19 good - - -  Tyr82 -65.6 7.09 good - - - 
Gln 27 -64.1 4.5 good - - -  Asn83 -62.3 4.99 good 3.9 0.62 -59 
Val 28 -67.8 5.25 good 4.98 0.74 -67  Gln84 -65.6 5.29 good - - - 
Asn 29 -64.2 6.11 good 2.63 0.98 -47  Arg85 -62.8 6.48 good - - - 
Ser 30 -67.9 5.7 good - - -  Lys86 -64.8 6.51 good - - - 
Leu 31 -66 3.77 good 4.18 0.59 -179,-61  Glu87 -68 7.59 good - - - 
Leu 32 -64.2 5.94 good 3.78 1.04 -57  Glu88 -65.1 6.39 good - - - 
Ser 33 -65.3 5.15 good 4.28 0.28 -179, -61  Glu89 -68.3 6.58 good - - - 
Glu 34 -64.8 3.97 good - - -  His90 -65.3 4.47 good - - - 
Ser 35 -68.8 10.2 good 4.06 0.56 -60  Thr91 -67.3 5.04 good 4.1 0.7 -60 
Gln 36 -94.2 16.1 good 8.14 0.28 -149,-91  Leu92 -62.6 4.34 good 3.7 0.86 -57 
Leu 37 -72.8 12.1 warn 6.13 0.30 -165, -75  Leu93 -61.7 4.27 good - - - 
Lys 38 -56.8 2.97 good - - -  Asp94 -65.6 6.37 good 3.5 0.21 -55 
Glu 39 -67.7 6.09 good 4.75 0.29 -175,-65  Lys95 -64.5 6.99 good - - - 
Ala 40 -74.8 12.4 good - - -  Leu96 -62.6 4.82 good 3.5 1.24 -55 
Leu 41 -76.8 12 warn 7.5 0.25 -154,-86  Thr97 -68.6 8.15 good - - - 
Glu 42 -73.6 7.68 good 5.2 0.26 -171,-68  Gln98 -63.8 1.7 good - - - 
Pro 43 -53.8 7.72 good - - -  Gln99 -65.9 3.45 good - - - 
Asn 44 -66.5 5.83 good 5.21 0.34 -171,-69  Leu100 -64.3 5.24 good - - - 
Lys 45 -66.3 5.59 good - - -  Gln101 -64.1 5.27 good - - - 
Arg 46 -62.6 2.94 good - - -  Gly102 -68.2 5.09 good - - - 
Gln 47 -62.3 4.03 good 4.20 0.38 -179,-61  Leu103 -64.9 3.92 good 4.97 0.51 -173,-67 
His 48 -67.3 6.38 good - - -  Ala104 -61 2.93 good - - - 
Ile 49 -62.8 4.72 good - - -  Val105 -65.4 8.38 good - - - 
Tyr 50 -65.1 3.51 good - - -  Thr106 -68.8 9.24 good - - - 
Gln 51 -62.9 4.12 good 4.12 0.57 -60  Ile107 -74.5 18.85 good - - - 
Arg 52 -67.3 6.4 good - - -  Ser108 -72.1 19.27 good - - - 
Cys 53 -60.7 5.66 good - - -  Arg109 -76.4 14.02 dyn - - - 
Ile 54 -63.7 8.58 good 4.54 0.57 -63  Glu110 -77.1 27.26 dyn - - - 
Gln 55 -63.2 2.93 good -  - -  Asn111 -94.43 24.7 dyn 7.62 0.07 -153,-87 
Leu 56 -64.3 4.11 good - - -  Ile112 -111.2 63.66 dyn - - - 
Lys 57 -59.2 4.45 good - - -  Thr113 -121-3 58.15 dyn - - - 
Gln 58 -64.3 4.13 good 4.59 0.39 -176,-64  Glu114 -116.2 63.56 dyn - - - 
Ala 59 -63.7 3.05 good 4.68 0.44 -176,-64  Val115 -123 66.02 dyn - - - 
Table 9. List of the phi angles predicted by TALOS+ and calculated by HNHα. TALOS+ columns indicate: 
φ: predicted φ angle, Dφ: predicted error angle, Q: quality (“good”, “warn” not good prediction keep attention, 
and “dyn” for dynamic residues). HNHα columns are: 3J: calculated value of the scalar coupling 3JHN,Hα, E: 
estimated error, φ: predicted φ angle.  
 
 
 
 
 92 
 
6.4.5 
1
H-
1
H NOE pattern of NPHP11-115 confirms the presence of α-helix 
 
 
To determine the solution structure of NPHP11-115 by NMR after  having assigned the domain 
resonances (
1
H, 
13
C, 
15
N) we performed and analyzed NOESY 2D and 3D spectra (
1
H-
1
H 
NOESY, 
1
H-
15
N NOESY and 
1
H-
13
C NOESY) to collect interproton NOE restraints 
(paragraph 4.2.8). NOE restraints are the most important experimental data for the calculation 
of a NMR solution structure, as they give a range of distances between two closely spaced 
1
H 
atoms (<5 A).  
A chart made by means of CCPNmr summarizes the secondary structure and the assigned 
1
H-
1
H NOEs of the domain [Figure 56]. The sequential NOEs between Hαi and H
N
(i+1) and 
between Hβi and H
N
(i+1) indicated as dαN and dβN, respectively, are found over all the protein 
sequence, whereas the sequential NOEs between H
N
(i) and H
N
(i+1), dNN, are missing at the N-
terminus region indicating the flexibility of the region. The regular secondary structure such 
as α-heli  or β-strands, forces protons in a well defined spatial relationship, thus generating a 
specific pattern of NOEs. Analysis of the NOE patterns (NOEs between Hαi and the H
N
i+3 and 
between Hαi and Hβi+3 indicated as dαN(i, i+3) and dαβ(i,i+3) respectively) reveals that the domain 
adopts α-helical conformation. This pattern of NOEs is found all along the structure: in the 
stretches comprising the residues 14 and 35, 45 and 69 and 88 and 108, that form three α-
helices. This result is in agreement with the model obtained with CS-Rosetta and with the 
secondary structure predicted by CSI. 
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Figure 56. The chart of the pattern of the NOEs made by CCPNmr. In this chart the NOEs assigned and the 
predicted secondary structure by CSI are summarized. 
 
 
 
6.4.6 Structure calculation 
 
 
We next calculated with ARIA 2.1.3 software
62
 the structure of the NPHP11-115 using 1561 
manually assigned NOEs restraints, 93 dihedral angles predicted by Talos + and 22 H-bonds 
as further restraints. The restraints used for final structure calculation are listed in table 10. 
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NOE distance restrains Unambiguous Ambiguous 
Intrasequential (0) 445 162 
Sequential ( | i-j | = 1) 307 109 
Short ( | i-j | = 2-3) 214 74 
Medium ( | i-j | = 4-5) 71 22 
Long ( | i-j | > 5) 124 31 
Total 1163 398 
Dihedral angles restrains 93 
H-bonds restrains 22 
Table 10. Restrains used to calculate the 20 lowest energy structures of the NPHP1. The NOEs are 
classified according to the distances between the residues. 
 
 
The best ensemble of structures achieved up to now for NPHP11-115 is reported in Figure 57. It 
represents the 20 lowest energy structures calculated by ARIA2.1.3 software after refinement 
in water. The statistics associated to the bundle of the structures is summarized in table 11.  
 
 
RMSD (Å) 
Residues 14-108 (excluding N- and C-termini) 1.336+/-0.271 
Only helices (14-32; 44-69; 83-108) 0.890 +/- 0.180 
Structural quality 
% residues in most favored regions 84.1 
% residues in additionally allowed regions 12.9 
% residues in generously allowed regions 1.7 
% residues in disallowed regions 1.4 
Table 11. Statistics of the 20 lowest energy structures of the N-terminus of NPHP1. RMSD is calculated on 
N, Cα and C’ atoms. Ramachandran quality parameters are assessed using the PROCHECK-NMR software82. 
 
 
The NPHP11-115 adopts a well defined tertiary structure, it is a right-handed 3-stranded α heli  
bundle composed by three antiparallel α helices: α1, Leu14 – Leu32, α2, Asn44 –Lys69, α3, 
Asn83- Ser108, connected by short linkers: loop1: Leu 33- Pro 43; loop2: Leu 70- Tyr 82. 
The N- and the C- termini comprising residues Gly1- Pro13 and Arg109- Thr119 respectively 
are flexible. The second helix does not show any curvature, whereas the first and the third 
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helix show a kink at the residue Arg 19 and the Glu 99 respectively, for this reason the three 
helices are not coaxial. The backbone RMSD calculated considering the residues belonging to 
the three α-helices is 0.890 +/- 0.180 Å, we have excluded the N- and C-termini and the 
interhelical regions. The RMSD calculated overall the structure, excluding the N- and the C- 
termini, is reported in table 11.  
To compare the NMR ensemble of the structure and the model obtained with CS-Rosetta we 
have also calculated the RMSD between them considering only the three α helices. The 
RMSD calculated on the backbone is 1.76+/- 0.18. Hence the model obtained with CS-
Rosetta is very similar with the solution structure. 
 
 
 
Figure 57. The NPHP11-115 structure. Cartoon representation of the NMR ensemble of the 20 lowest energy 
structure of NPHP11-115. Superimposition has been performed on the N, Cα and C’ atoms of the residues 
belonging to the α-helices. The structure in the right side of the panel is related to the former by a 180° rotation. 
 
 
The protein core is formed by hydrophobic contacts between the side chains of a significant 
number of hydrophobic residues pointing towards the interior of the helix bundle. In 
particular  hydrophobic contacts occur between the Leu 103-Leu 31, Leu 24- Ile 60, Leu 17- 
Leu 67, Leu 100-Ile 49, Leu 100-Val 28 [Figure 58A]. The structure is further stabilized by 
polar contacts that occur between the second and the third helix . These polar contacts  
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involve the following residues: Lys 57-Glu 101, Lys 64-Asp 94; His 90-Gln 68 [Figure 58B]. 
However, the majority of the polar side chains of the polar residues are exposed to the solvent 
thus creating a highly charged surface [Figure 59]. In particular the charges are randomly 
distributed on the surface of the structure. 
 
 
 
 
 
Figure 58. The contacts that stabilize the structure. A. The hydrophobic core of the structure. B. The polar 
contact that stabilize the structure between the α2 and the α3. 
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Figure 59. Electrostatic surface of NPHP11-115. The charge is randomly distributed on the surface . The 
structure on the right side  is related to the left by a 180° rotation. Blue and red indicate positive and negative 
electrostatic surface potentials, respectively.  
 
 
To gain insights into the relative orientation of the three helices, we performed residual 
dipolar coupling (RDC) measurements on a 
15
N-labelled NPHP11-115 sample. We considered 
only the RDC values for residues that belong to the structured regions. The RDC values of 46 
residues satisfied this requirement.  
We used PALES 
71
 to calculate the Q factors of the 20 lowest energy structures for the 46 
RDC values experimentally calculated and the structure #3 displays the best agreement with 
these RDC values (Q factor: 0.55). The measured RDCs were compared to the values back 
calculated from NPHP11-119 structure#3 using MODULE
69
. As shown in Figure 60, the two 
set of data set are overall in agreement. 
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Figure 60. Comparison of experimentally measured RDC values and RDC values back-calculated from 
the calculated structures. Plot of the measured RDC versus the RDC values back-calculated from structure #3.  
 
 
A search using the DALI server 
83
 for NPHP11-115 was performed to compare our calculated 
structures with those present in the Protein Data Bank. Unfortunately from this search we did 
not obtain any structure similar to the NPHP11-115.  
 
 
 
6.4.7 NPHP11-115 displays three structured regions 
 
 
In order to obtain information on the local backbone dynamics we performed heteronuclear 
relaxation NMR experiments including T1 and T2 relaxation and heteronuclearNOE 
(hetNOE) experiment.  Results deriving for heteronuclear NOE (hetNOE) and T1 relaxation 
give information on the local backbone flexibility in the ns-ps time-scale, as they are sensitive 
to the high-frequency motions whereas the T2 relaxation rate is also influenced by slow 
motion in the μs-ms time-scale 84.  
The hetNOE value for each HN group of the protein backbone, ranges from -1 to 1, they are 
calculated as described in Eq. 6 in chapter 4.2.10, [Figure 61]. Residues in highly structured 
regions (including α1, α2, α3) move in a coherently way with the protein rotational diffusion 
tensor and have an hetNOE value between 0.8 and 1. On the contrary, residues in the flexible 
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regions (including  res 1-14, 37-43, 70-87 and 109-119), such as loops and N- and C-termini, 
have typically hetNOE value <0.5. 
 
 
 
Figure 61. The NPHP11-115 heteronuclear NOEs for local backbone flexibility. The first 14 residues and the 
11 residues corresponding to the N- and the C-terminus respectively show hetNOE value <0.5, it indicates the 
high backbone mobility at the ns-ps time-scale. Some flexibility is also found in the residues at the interhelical 
connecting loops (residues Leu 37- Pro 43, Leu 70- Tyr 82). Whereas the hetNOE value >0.6 of the three helices 
α1, α2 and α3 indicates a restricted dynamic. 
 
 
The T1 relaxation rate is expressed as R1 (1/T1), as a frequency. Hence high R1 values 
indicate a high dynamics of the HN backbone whereas low values indicate a restricted 
dynamics of the HN backbone [Figure 62]. Residues in highly structured regions, the three 
helices α1, α2, α3 in our case, present a low value of R1 relaxation rate. On the contrary, 
residues in the flexible regions (including  res Gly 1-Pro 13, Leu 37- Pro 43, Leu 70- Tyr 82 
and Arg 109- Thr 119), such as loops and N- and C-termini, have a high value of R1 relation 
rate.  
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Figure 62. The NPHP11-115 R1 relaxation rate. The first 14 residues and the last 11 residues corresponding to 
the N- and the C-terminus respectively show a high R1 value such as the residues at the interhelical connecting 
loops (residues Leu 37- Pro 43, Leu 70- Tyr 82), whereas the three helices α1, α2 and α3 show a low value of R1 
relaxation rate. 
 
 
Like T1 relaxation rate, also T2 relaxation rate is expressed as R2 (1/T2). High R2 values are 
usually indicative of motions in this slow time scale or chemical exchange. High R2 value are 
observed for the three helices (α1,α2 and α3) whereas the N- and C- terminus and the 
interhelical loops have a low R2 value [Figure 63]. 
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Figure 63. The NPHP11-115 R2 relaxation rate. The first 14 residues and the last11 residues corresponding to 
the N- and the C-terminus respectively show a low R2 value such as the residues at the interhelical connecting 
loops (residues Leu 37-Pro 43, Leu 70-Tyr 82),  whereas the three helices α1, α2 and α3 show a high value of R2 
relaxation rate. 
 
 
Through T1 and T2 relaxation measurements and heteronuclearNOE (hetNOE) NMR 
experiments we have investigated the backbone dynamics of the NPHP11-119 confirmed the 
presence of three structured regions, corresponding to the α helices (α1: Leu14 – Leu36, α2: 
Asn44 –Lys69, α3: Asn83- Ser108), connected by two short linkers (loop1: Leu37- Pro43; 
loop2: Leu70- Tyr82) that display flexibility as the N- and the C- termini comprising residues 
Gly1- Pro13 and Arg109- Thr119, respectively. 
The average value of the 
15
N R2/R1 ratio over a protein backbone allows the determination of 
the molecular rotational correlation time (τC, the average time for a molecule to reorient about 
one radian) under two conditions: 
 
 the presence of motions in ps-ns time scale are not significant (conventionally residues 
presenting hetNOE<0.65 are excluded from this analysis)  
 
 R2 is not significantly lengthened by chemical or conformational exchange85.  
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We thus calculated the average value of R2/R1 considering the 101 residues that satisfy the 
aforementioned conditions, and computed the τC according to empirical equation 11. 
 
 


2
7126
N
RR
c

          eq.11 
 
where ωN and <R2/R1> indicate the 
15
N resonance frequency and the average R2/R1 ratio, 
respectively. For NPHP11-119, <R2/R1>= 20.382, so the calculated τC is 14.056 +/ -2.457 ns, 
which is in agreement with the expected rotational correlation time of a protein of this 
dimension.  
 
 
 
6.5 The interaction with the coiled coil domain of PC1 
 
6.5.1 The purification of the recombinant coiled coil domain of PC1 
 
 
In order to investigate the interaction between NPHP11-115 and the coiled coil domain of PC1 
(CC_PC1) by NMR we first produced the CC_PC1 (spanning residues His 4186 to Ala 4257) 
with recombinant techniques. The CC_PC1 DNA sequence was cloned in pETM44 plasmid 
and purified from E. Coli (paragraph 4.2.1). The purified construct has the following 
sequence, where the amino acids belonging to the tag and that remain after the protease 
cleavage are highlighted in italics: 
 
GPMGHPSTSSSQLDGLSVSLGRLGTRCEPEPSRLQAVFEALLTQFDRLNQATEDVYQL
EQQLHSLQGRRSSRAPA 
 
We tried to purify the domain without the tag but the protein was aggregated, for this reason 
we were not able to reach high protein concentrations. Figure 64 shows a 1D NMR spectrum, 
the broad line width of the spectrum confirmed that the protein is aggregated and not suitable 
for further structural studies. 
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Figure 64. The 1D 
1
H NMR spectrum of CC_PC1. CC_PC1 used for spectrum was concentrated 0.3 mM and 
dissolved in PBS 20mM, 3mM DTT, spectrum was recorded at 298K. 
 
 
In a previous study aiming to investigate by NMR the interaction between the coiled coil 
domain of polycystin 2 and the coiled coil domain of PC1
19
 the authors have used the 
recombinant coiled coil domain of PC1 with the His-MBP tag. We therefore decided to purify 
the protein with MBP tag, in order to improve its solubility and to avoid aggregation. 
Unfortunately, also this construct displays aggregation. We recorded the 1D 
1
H spectrum that 
displays more signal dispersion but the peaks are broad due to the high molecular weight of 
the MBP [Figure 65].  
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Figure 65. The 1D 
1
H NMR spectrum of His-MBP-CC_PC1. His-MBP-CC_PC1 used for spectrum was 
concentrated 0.3 mM and dissolved in PBS 20mM, 3mM DTT, spectrum was recorded at 298K. 
 
 
6.5.2 Titration of 6His-MBP-CC_PC1 into NPHP11-115  
 
 
Despite the low sample concentration and the high aggregation state of the protein we have 
tried to perform a titration with 
15
N labeled NPHP11-115. to prove binding between 6His-MBP-
CC_PC1 and NPHP11-115. We recorded a spectrum of 
15
N NPHP1 in the presence of PC1 (1:1 
stoichiometry) [Figure 66, the black and the red  spectra represent NPHP11-115 in absence or 
presence of PC1 respectively]. 
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Figure 66. The NPHP11-115 appears to do not bind the CC_PC1. The 
1
H-
15
N HSQC spectra of 
15
N NPHP11-115 
alone (black) and after the addition of a 1-fold molar excess of CC_PC1(red). 
 
 
Because of the low concentration of the recombinant CC_PC1 we have added 182 μl of ligand 
concentrated 0.4 mM to a solution containing a volume of 250 μl of the 15N NPHP11-119 
concentrated 0.3 mM leading to a dilution of the sample. Addition of 6His-MBP-CC_PC1 to 
15
N NPHP11-115 did not cause any chemical shift displacement, suggesting the absence of 
interaction between the two domains. 
However few NPHP1 residues (Leu 14, Leu 92, Leu 96 and Leu 103) showed decrease of 
intensity upon addition of CC_PC1, we cannot therefore completely exclude the hypothesis of 
the interaction between CC_PC1 and NPHP11-115. The interaction will be object of further 
investigations. In particular we will perform GST pull down between the entire C- tail of PC1 
and NPHP11-115 and we will optimize the purification of the CC_PC1 using a longer construct 
in order to stabilize it. 
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7. Discussion 
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7.1 Metabolomics 
 
 
7.1.1 Metabolomic profiling of the exometabolome of Pkd1 KO and WT MEF cells. 
 
 
In this thesis we have used solution state NMR to analyze the metabolome of the medium 
conditioned by Pkd1 KO and WT MEF cells. The analysis has highlighted some metabolic 
differences between the two exometabolomes confirming the hypothesis that PC1 acts as 
“metabolic regulator”.  
Importantly, the metabolic profiling of the Pkd1 KO MEF cells’ e ometabolome revealed 
similarities with tumor metabolism, as Pkd1 KO MEF cells produce high levels of lactate, 
alanine and glutamate, similarly to what observed in cancer cells
9
. The production of lactate 
derives from a major consumption of glucose, hence the Pkd1 KO cells switch to aerobic 
glycolysis. This phenomenon will be discussed in the next paragraph, as it is been the main 
object of this thesis.  
The high secretion of alanine observed in Pkd1 KO MEF is most probably due to the high 
level of alanine aminotransferase (ALT), that converts pyruvate into alanine, and can be 
explained as a metabolic solution found by the cells to eliminate the large excess of carbon 
and nitrogen, toxic for the cells, deriving from the accelerated metabolism
9
. In this context, to 
support this hypothesis, it would be interesting to investigate by transcriptomics whether Pkd1 
KO cells display higher transcripts of ALT, as observed in tumor cells
9
.  
Conversely, the high content of secreted glutamate observed in Pkd1 KO MEF cells’ 
exometabolome might be related to a stimulus to promote cell survival, growth and 
proliferation through metabotropic glutamate receptors (mGluRs), such as the G-proteins-
coupled-receptors, that leads to a stimulation of ERKs pathway and phosphaditilinositole 3’-
kinase
10,11
. The high level of glutamate, which is usually present in low levels in the 
extracellular medium, might derive from the conversion of extracellular glutamine, which is 
generally a high abundant nutrient of the extracellular medium. Glutamine enters into the cell 
and is converted into glutamate by a mitochondrial enzyme, the glutaminase (GLS), glutamate 
can accumulate inside the or can be secreted outside the cell. This process, called 
glutaminolysis, is a hallmark of the tumor metabolic pathway
9
. But in this case the metabolic 
profiling of the medium conditioned by Pkd1 KO cells displays only a major production of 
glutamate whereas the Pkd1 KO cells do not show a major consumption of glutamine. Also in 
this case it would be interesting to verify whether Pkd1 KO cells, similarly to tumor cells, 
 108 
 
display high levels of GLS transcript. Taken together, these metabolic findings indicate that 
the Pkd1 KO MEF cells are affected by an accelerated metabolism related to their increased 
proliferation rate, once again suggesting similarities between the metabolic dysfunctions 
occurring both in tumor cells and in Pkd1 KO MEF. 
 
 
7.1.2 The Warburg effect occurs both in cellular models and in vivo 
 
 
The most relevant metabolic difference distinguishing Pkd1 KO from WT MEF cells consists 
in the presence of increased levels of aerobic glycolysis, the Warburg effect, as highlighted by 
the increased lactate production and by the increased glucose consumption observed in Pkd1 
KO MEF cells as compared to WT cells. 
The Warburg effect is a metabolic hallmark of cancer and proliferative cells, which adopt this 
metabolic strategy to sustain the high energetic demand required by the increased 
proliferation rate. Usually, cells of differentiated tissues metabolize glucose to produce ATP 
through oxidative phosphorylation, whereas in presence of oxygen cells of proliferative or 
tumor tissues produce ATP through  glycolysis converting glucose into lactate, the principal 
end product of this pathway [Figure 67]. Similarly to tumor and proliferative cells Pkd1 KO 
MEF cells display an increased proliferative rate thus requiring more energy production as 
compared to the WT cells. 
In order to prove that the Warburg effect occurs also in vivo we analyzed the glucose and 
lactate content in kidneys deriving from Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+ 
mice
12
. 
Unfortunately, the analysis of 1D 
1
H NMR spectra of the polar extracts of WT and KO 
kidneys did not confirm our hypothesis, as the measurements were affected by high errors 
generated by the high biological variability between the analyzed litters. We therefore decided 
to treat Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+ 
mice with uniformly labeled 
13
C glucose in order to 
better follow the conversion of glucose into lactate. The use of stable isotope is an 
experimental procedure widely applied in order to trace a specific metabolite in cells and in 
animal models
13,14
. This technique is very useful to confirm a specific metabolic pathway 
associated to a particular disease and to verify whether a drug produces the expected effects. 
The analysis of the polar extracts of the kidneys deriving from Ksp-Cre: Pkd1
flox/- 
and 
Pkd1
flox/+  
mice treated with uniformly labeled 
13
C glucose allowed us to confirm that the 
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Warburg effect arises also in vivo. In fact Pkd1 KO kidneys displayed an increased amount of 
glucose and lactate compared to WT kidneys.  
Finally, the analysis of the transcripts of the glycolytic enzyme through real-time PCR 
analysis, performed by our collaborators, has revealed that Pkd1 KO cells and Pkd1 KO 
kidneys displayed a transcriptional signature of the glycolytic enzymes, thus supporting our 
metabolomic findings. 
 
 
 
Figure 67. The fate of the glucose in differentiated (on the left) and in proliferative or tumor tissues (on 
the right). Glucose in differentiated tissues is used to produce ATP through the oxidative phosphorylation, 
whereas proliferative and tumor tissues produce ATP through the aerobic glycolysis. [Figure from Vander 
Heiden, et al. Science, 2009]. 
 
 
 
7.1.3 Signaling cascade 
 
 
The observation that Pkd1 KO MEF cells and Pkd1 KO kidneys are affected by the Warburg 
effect inspired further experiments to investigate the deregulated signaling cascade deriving 
from loss of functional PC1. These experiments were performed by our collaborators. A 
previous study 
41
 showed that the loss of PC1 enhances the activity of mTORC1 through the 
up-regulation of the ERKs pathway. The enhanced mTORC1 activity causes the increase of 
the cell size and the cellular proliferative rate thus inducing the Warburg effect. The 
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accelerated metabolism in absence of functional PC1 increases also the intracellular ATP 
content, inhibiting AMP-activating protein kinase (AMPK), an enzyme that acts as metabolic 
regulator detecting the AMP:ATP ratio to maintain the energy homeostasis. In addition, 
AMPK is also regulated upstream by phosphorylation of LKB1
75
in an ERKs pathway 
dependent manner. Hence, summarizing the Warburg effect, due to the loss of PC1, depends 
on the up-regulation of ERK pathway. ERKs pathway act in a dual manner: inhibiting the 
LKB1-AMPK axis on the one hand while activating the mTORC1-glycolytic cascade on the 
other. Enhanced metabolic rates further inhibit AMPK. 
 
 
7.1.4 Treatment with drugs 
 
 
We next wondered whether each step of the signaling cascade generated by the loss of PC1, 
including also the Warburg effect, could be targeted and restored to basal levels using FDA 
approved drugs. We have therefore treated in separated experiments Pkd1 KO and WT MEF 
cells with rapamycin, to inhibit the mTORC1 activity and with metformin and with AICAR, 
to activate AMPK. We also treated Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+ 
mice with 2-deoxy-
glucose (2DG) in order to test its effects on aerobic glycolysis. 
 
 
Cells’ treatments with rapamycin, metformin and AICAR. We observed that the separated 
treatments  with rapamycin, metformin and AICAR were able to partially restore the 
deregulated signaling cascade involving ERKs, mTORC1 and AMPK in Pkd1 KO cells, 
whereas they did not have effect on the WT cells, however the analysis of the exometabolome 
of the treated Pkd1 KO and WT MEF cells revealed that these drugs were not able to revert 
the metabolic phenotype. At variance to our expectations the exometabolome of the treated 
Pkd1 KO MEF cells displayed a higher consumption of glucose and a higher production of 
lactate compared to the exometabolome of not treated Pkd1 KO MEF cells. The treatments 
appears therefore to induce an enhanced aerobic glycolysis. This effect was partially expected 
for the treatment with metformin, as lactic acidosis is a known side effect of this drug
78
. 
Conversely, based on the inhibitory activity of rapamycin on mTORC1, we expected that this 
drug could partially restore the physiological levels of the aerobic glycolysis. However from 
our results we conclude that rapamycin in this context does not influence the Warburg effect. 
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Concerning AICAR, we were expecting that its inhibition role in the signaling cascade might 
also restore the aerobic glycolysis at  physiological levels, however our results did not provide 
any evidence of its restoring influence. Interestingly, both rapamycin and AICAR lead to 
increased levels of lactate.  
 
 
Treatment with 2-deoxy-glucose (2DG). We tested in vivo the efficacy of 2DG, an analog of 
glucose that blocks directly the glucose metabolism, acting as a competitor of the glucose. 
After simultaneous treatment of Ksp-Cre: Pkd1
flox/- 
and Pkd1
flox/+
mice with 2DG and 
13
C 
glucose we analyzed the glucose and lactate content in liver and kidney. After treatment with 
2DG we observed an improvement of the glucose metabolism in Pkd1 KO kidneys, which 
showed a decrease in lactate content compared to not treated Pkd1 KO kidneys; the glucose 
content in WT and KO kidneys mice remained very similar. This result indicates that the 
treatment with 2DG blocks the glucose metabolism without interfering with the glucose 
uptake. Moreover, Pkd1 KO kidneys treated with 2DG displayed also an improvement of the 
kidney histology displaying a reduction of cysts’ volume and consequently a reduction of   
10% of the kidneys' weight (the weights of  not treated and 2DG treated kidney’s were   210 
mg,   190 mg, respectively). These preliminary results on the efficacy of 2DG treatment in 
ADPKD mouse model are very encouraging and suggest that glucose metabolism could be a 
promising target for a pharmacological therapy. 
 
 
7.1.5 Conclusions and future perspectives 
 
 
Metabolomics is widely used to discover disease biomarkers and to understand which 
metabolic pathways are deregulated in a particular disease
86,87
. Through this approach we 
have confirmed the hypothesis that PC1 acts as “metabolic regulator” identifying the Warburg 
effect, as the most relevant metabolic change that occurs for the loss of PC1 both in cellular 
model and in mouse kidneys. Moreover the metabolomic approach allowed us to test the 
effect of the rapamycin, metformin and AICAR treatment on the aerobic glycolysis in cellular 
model. Importantly NMR metabolomics allowed us to trace the effects of 2DG treatment in 
vivo. In particular 2DG is the only drug able to partially restore the physiological levels of 
aerobic glycolysis showing also an improvement of the renal histology. 
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These results allow to expand our knowledge on the molecular mechanisms regulated by 
PC1and to get new insights into the complex mechanism underlying cystogenesis, thus 
opening new perspectives in novel therapeutic strategies for ADPKD.  
The study on the involvement of PC1 in the metabolic regulation is still at the beginning. In 
order to have a complete vision on the metabolic pathways regulated by PC1 we will 
investigate and compare the endometabolome, the entire set of intracellular metabolites, in 
Pkd1 KO and WT MEF cells. In addition we will compare the endometabolome of the cells 
not treated and singularly treated with AICAR, metformin and rapamycin in order to 
investigate the metabolic changes that occur under these pharmacological treatments. 
The analysis of the exometabolome of the Pkd1 KO cells has highlighted some metabolic 
similarities with the tumor metabolism, we will therefore study a cellular model for the renal 
carcinoma and the kidneys deriving from a mouse model of renal carcinoma and compare 
them with the cellular model and the mouse model of ADPKD in order to elucidate the 
similarities and the differences between the two diseases at metabolic level and at the level of 
the associated signaling cascade. 
 
 
7.2 Structure 
 
 
7.2.1 NPHP11-115 structure 
 
 
In this thesis we have exploited the solution state NMR also to solve the structure of the N-
terminus of NPHP1 and to investigate a possible interaction between the N-terminus of 
NPHP1 and the coiled coil domain of PC1. 
The first 115 amino acids of NPHP1 were predicted to be a coiled coil domain based on the 
analysis of its primary sequence, they were therefore expected to mediate homo-
oligomerization. Unexpectedly, the recombinant NPHP11-115 construct did not display 
oligomerization features, behaving as monomer in solution, as assessed from gel filtration 
elution volume and from the value of the rotational correlation time τc, 14.056 +/- 2.457 ns, 
which corresponds to the values associated to a protein of 13kDa. 
In addition NPHP11-115 showed high thermostability with a melting temperature of 65°C. Its 
secondary structure is characterized by a high α helical content (  45%), as estimated from the 
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analysis of its CD spectrum. In line with the estimated secondary structure content, the 
solution structure of NPHP11-115 displays a three- helix bundle fold. In detail, the N-terminus 
of NPHP1 shows a right-handed helix bundle, composed by three antiparallel α helices 
connected by short linkers, whereas the N- and the C- termini display high motility. The three 
helices are not completely coaxial, as the first and the third helix show a kink at residues Arg 
19 and the Glu 99, respectively. 
The structure is mainly stabilized by hydrophobic interactions with a significant number of 
side hydrophobic chains  (Leu 103-Leu 31, Leu 24- Ile 60, Leu 17- Leu 67, Leu 100-Ile 49, 
Leu 100-Val 28) pointing towards the interior of the helix bundle. Most of the side chains of 
the polar residues are solvent exposed, therefore the surface of the protein is highly charged 
showing a random distribution of the charges. Only a few polar residues interact between the 
second and the third helix in order to stabilize the structure (Lys 57-Glu 101, Lys 64-Asp 94; 
His 90-Gln 68). 
The function of this domain is still unknown. Helix bundles, similarly to coiled coil domains 
are also involved in protein-protein interactions, in particular they usually interact with 
cytoskeleton proteins such as actin. This is in agreement with the known role of NPHP1 in the 
organization of a protein complex where it regulates the actin cytoskeleton at sites of 
epithelial cell-cell adhesion through the binding between the NHD domain with filamin 
family protein of actin- binding protein
4
. 
NPHP mutations do not involve this domain
88
; however they are located at the C-terminus of 
the three helix bundle in a non structured region, suggesting that pathological mutations do 
not affect the protein fold, but are rather related to a functional role. 
The supposed interaction between the coiled coil domain of PC1 (CC_PC1) and the helix 
bundle of NPHP1 could not be demonstrated in this thesis. The 
1
H-
15
N HSQC recorded after 
the addition of CC_PC1 with the tag to NPHP11-115 did not display any chemical shift 
displacement. However we observed the decrease in intensity of some peaks which could 
suggest a possible binding (specific or aspecific). For this reason we cannot totally exclude a 
possible interaction between the two domains and further experiments are needed to clarify 
this point. 
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7.2.2 Conclusions and future perspectives 
 
 
In conclusion from these structural studies we learned that NPHP11-115 is not a coiled coil 
domain but a stable monomeric three helix bundle. This is the first experimental evidence that 
highlights the presence of this structural element at the N-terminus of NPHP1. 
We could not verify a direct binding between CC_PC1 the N terminus of NPHP1 and further 
investigations are needed to clarify this aspect. To this aim we will perform GST pull down 
experiments using the helix bundle of NPHP1 and the entire C-tail of PC1 which contains the 
coiled coil domain. In addition, we will try to improve the purification of the CC_PC1 using a 
longer construct (spanning residues His 4186 -Ala 4272) that comprises the coiled coil 
structure and the second poly proline motif, in order to stabilize and improve the solubility of 
the recombinant CC_PC1.  
It is  known that the second poly proline motif of PC1 and the SH3 domain of NPHP1 interact 
with a low affinity
17
, therefore, in order to test if the presence of the CC_PC1 and the 
NPHP11-115 can improve the affinity of the complex, we will titrateof the first 220 amino acids 
of NPHP1, which comprise both the helix bundle and the SH3 domain, into the longer PC1 
construct, which comprises the coiled coil structure and the second poly proline motif 
(spanning residues Pro 4267 - Arg 4272), using isothermal titration calorimetry (ITC) as 
technique.  
 
 
Part of the results of this thesis have been accepted for publication in Nature Medicine 
“Defective Glucose Metabolism in Polycystic Kidney disease Identifies A Novel Therapeutic 
Paradigm”. Rowe I., Chiaravalli M., Mannella V., Ulisse V., Quilici G., Song X., Xu H., 
Pema M., Mari S., Qian F., Pei Y., Musco G., Boletta A. 
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8.1 NMR appendix 
 
 
8.1.1 Chemical shift 
 
 
Nuclei present a fundamental quantomechanical property, the nuclear spin whose value can be 
a multiple of ½ and can be positive or negative. Nuclei presenting non zero nuclear spin show 
a nuclear magnetic moment and can be investigate by nuclear magnetic resonance (NMR).  
If an external magnetic field is applied, called B0 and conventionally described as directed 
along the z axis, they will align with B0 or opposite to it: this phenomenon is called the 
Zeeman effect. Spins inside a static magnetic field will precess around B0. The frequency of 
this precession, called Larmor frequency of the spin (ω0), is dependent on the applied 
magnetic field B0 and the γ, the gyromagnetic ratio, a property of each particular type of 
nucleus, according to the following equation: 
 
ω0 = - γ B0          eq.12 
 
The chemical shift represents the dependence of nuclear magnetic energy level on the 
chemical environment. Electrons in the molecular orbitals surround nuclei and create small 
local magnetic fields which slightly shield nuclei from the external magnetic field. 
Consequently, the total magnetic field experienced by each nucleus includes the local 
magnetic fields induced by the currents of electrons [Figure 68].  
 
 
 
Figure 68. Electrons in the molecular orbitals surround nuclei and create small local magnetic fields which 
slightly shield nuclei from the external magnetic field. 
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The electron distribution of the nuclei with the same nuclear spin (e.g. 
1
H, 
1
3C, 
15
N) usually 
varies according to the local geometry (binding partners, bond lengths, angles between bonds, 
etc.) thus changing the local magnetic field around each nucleus. This is reflected into the 
slightly different energy levels for chemically different spin . The variation of resonance 
frequencies of the same kind of nucleus due to variations in the electron distribution is called 
chemical shift.  
The size of the chemical shift of each nucleus (νi) in the molecule is given with respect to a 
reference frequency or reference sample (νDSS), usually DSS (2,2-dimethyl-2-silapentane-5-
sulfonic acid) for proteins, to which is assigned the chemical shift of zero, expressed in Hertz 
(Hz), whereas the denominator (ν0) represents the operating frequency of the magnet, 
expressed in Megahertz (MHz). Chemical shift (δ) is calculated from: 
 
 
0

 DSSi

           eq.13 
 
Since the numerator is usually in Hertz(Hz), and the denominator in MegaHertz(MHz), 
chemical shift is expressed in ppm (parts per million). The resonance frequencies depend on 
the applied field but the chemical shift is independent of it. On the other hand the resolution 
of a NMR spectrum will increase with applied magnetic field, resulting in better lines (peaks) 
separation. 
Different chemical groups have different chemical shifts due to their dependence on the 
chemical environment. This is one of the major information sources in NMR spectra [Figure 
69]. 
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Figure 69. 1D 
1
H protein spectrum.  
 
 
 
8.1.2 Magnetization transfer 
 
 
Nuclear spins interact through two different mechanism: scalar coupling (also named spin-
spin coupling) and dipolar interactions.  
Scalar coupling originates from the interaction between  bond electrons, thus it occurs only 
between atoms covalently bound and it decreases with the number of  chemical bonds that 
separate the two nuclei. It depends on the coupling constant J, that is expressed in Hertz (Hz), 
and does not depend on the applied magnetic field.  
Dipolar interactions, instead, occur between nuclei that are close in the space, they can be 
detected only for nuclei which are less than 5 Å apart. These interactions drop off very fast 
with the distance, as they depend on the inverse of the sixth power of the distance (1/r
6
). 
Nuclear Overhauser Enhancement (NOE) relies on dipolar interactions. 
The magnetization can be transferred through these two mechanisms between nuclei of the 
same kind (homonuclear experiments) or between nuclei of different kinds (heteronuclear 
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experiments). In the homonuclear experiments the magnetization is transferred, through scalar 
coupling or dipolar interactions, among nuclei of the same type, generally 
1
H. Radio 
frequency pulses are applied along  only one channel of the NMR spectrometer. In 
heteronuclear experiments, magnetization is transferred among different types of nuclei, 
generally 
1
H, 
15
N and 
13
C nuclei, always through scalar coupling. In this case two or more 
channels are used (one is always dedicated to 
1
H and one or two for the heteronucleus/i) and 
the pulse sequence contains one or more pulse block, generally the INEPT (Insensitive Nuclei 
Enhances by Polarization Transfer) block, that transfer magnetization through the 
heteronuclear J coupling from 1H nuclei to low γ heteronuclei (i.e. 15N and 13C).  
An example is the 
1
H-
15
N HSQC. The basic pulse sequence of the 
1
H-
15
N HSQC comprises 
three blocks before detection. Block A is the INEPT (Intensive Nuclei Enhances by 
Polarization Transfer) pulse block that creates the 
1
H antiphase magnetization and transfers it 
from 
1
H nuclei to low  heteronuclei through heteronuclear scalar coupling. The time delay 
Δ/2 is set as near as possible to 1/(4J) to maximize the magnetization transfer, where J is the 
scalar coupling among the two nuclei (in this case JHN for the 
1
H-
15
N HSQC). Block B is a 
spin echo block in which 
15
N nuclei magnetization evolves with its chemical shift. The 
evolution time t1 is incremented at each repetition of the pulse sequence through the same 
increment of t1, in order to generate the second (indirect) dimension. 
1
H coupling and 
1
H 
chemical shift evolution during step B is removed through a 180° pulse applied only on the 
1
H 
channel at mid evolution time. Block C is simply a reversal of the initial INEPT sequence 
(that is, all pulses and delays are applied in reverse order, with the phase of the 90° pulses 
inverted) except that the first pulse has been removed. The double 90° pulse applied to both 
nuclei at the beginning of step C transfers magnetization from 
15
N back to 
1
H as an antiphase 
magnetization, which is then refocus during the last 2(Δ/2) delay. 
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Figure 70. The basic pulse sequence of 
1
H-
15
N HSQC. Block A represented the INEPT, block B the evolution 
of magnetization on the heteronuclei, block C the reverse INEPT. 
 
 
The NMR experiments can be divided in two classes according to the mechanism of nuclear 
spin interaction that is employed to transfer magnetization during the mixing time. In the 
NMR experiments used to assign the molecular resonances, magnetization is transferred 
through scalar coupling, hence the achieved 2D and 3D spectra show peaks for nuclei that are 
chemically bound to each others. To solve the structure of a molecule we need information on 
the spatial relationships among nuclei and 2D and 3D NMR experiments are employed in 
which magnetization is transferred between nuclei through dipolar interactions. The 2D and 
3D NOESY spectra show only peaks for nuclei  less than 5-6Å apart, irrespectively if they are 
chemically bound or not. 
 
 
8.1.3 Nuclear Overhauser Enhancement (NOE) 
 
 
The Nuclear Overhauser Enhancement (NOE) effect is due to dipolar interactions between 
nuclei. Dipolar interactions drop off very fast with the distance, hence only a proton-proton 
distance (
1
H-
1
H NOE) can occur with a distance 5-6Å. The intensity of an NOE peak depends 
on the inverse of the sixth power of the average distance between them (<r>) and the 
correlation function f(τc), which describes the modulation of the dipolar coupling by a 
stochastic process with an effective correlation time τc (eq. 14)  
 
NOE ∝ ( 1 / <r6> ) f(τc)         eq.14 
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1
H-
1
H NOE distances in proteins can be classified as: 
 
 intra-residue: between the 1H protons of the same residue; 
 
 sequential: between the backbone 1HN protons or between 1HN and aliphatic  protons in 
consecutive residues; 
 
 medium-range: all non sequential distances with a segment of five consecutive residues; 
 
 long-range: all other inter-residue distances among protons. 
 
The secondary structures, α-helices and β-strands, force protons in well defined spatial 
relationships. Consequently some 
1
H-
1
H NOE patterns are indicative of the stretches of 
secondary structure in protein. For e ample α-helices are characterized by proximity between 
the residues i and i+3 and the residues i and i+4, therefore in the 
15
N-HSQC-NOESY 
spectrum NOEs between the HNi and HNi+2 and HNi+3, HNi and Hαi+3 would be visible. In β 
strands short-medium range distances are usually absent because the individual strands 
consist of almost fully e tended polypeptide segments. Residues folded in β-sheets are rather 
characterized by short-sequential and long-range backbone 
1
H-
1
H NOEs. 
 
 
 
8.1.4 Monodimensional (1D) NMR experiments 
 
 
1D 
1
H experiment is the simplest NMR experiment and it consists of two sections: 
preparation and detection [Figure 71A]. During preparation the sample is subjected to an 
appropriate radiofrequency pulse (or series of pulses), while during detection the resulting 
signal is recorded. In the simplest case the preparation is a 90° pulse which rotates the 
equilibrium magnetization Mz onto the y axis (My). After this pulse each spin precesses with 
its own Larmor frequency around the z axis and induces a signal in the received coil, named 
free induction decay (FID). Usually the experiment is repeated several times and the data are 
summed up to increase the signal to noise ratio. After summation the data are Fourier 
transformed to yield the final 1D spectrum [Figure 71B]. 
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Figure 71. 1D NMR spectrum A. Schematic pulse sequence of 1D spectrum B. FID, a time-domain function, is 
transformed in a frequency-domain function through the Fourier transform. 
 
 
Proteins contain a large number of hydrogen atoms, so their 1D spectra contain peaks heavily 
overlapping [Figure 69]. Multidimensional spectra spread these signals over another 
dimension and allow to correlate the frequencies of different nuclei. 
 
 
 
8.1.5 Bidimensional (2D) NMR experiments 
 
 
Bidimensional (2D) spectra contain two additional blocks with respect to monodimensional 
spectra: the evolution and mixing time [Figure 72A]. The pulse sequence is repeated n  times, 
incrementing the t1 time delay of the evolution block at each repetition. The n FIDs generated 
by the pulse sequence repetitions will show a signal with a decaying sinusoidal trend 
depending on t1 (as opposed to the sinusoidal trend of each FID, which depends on t2). The 
Fourier transformation (FT) can be applied twice to a function depending on two time 
variables, generating a bidimensional spectrum with two independent frequency dimensions, 
Ω1 and Ω2, corresponding to t1 and t2, respectively [Figure 72B]. The correlation between 
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the two dimensions is built during the mixing time by means of adequate radio frequency 
pulses which drive the magnetization transfer among interacting nuclear spins.  
 
 
 
Figure 72. 2D NMR spectrum A. Schematic pulse sequence of 2D spectrum NMR B. Schematic representation 
of the FT on a series of FIDs depending on two time variables. 2D spectra are usually presented as contour plots, 
as shown in the box after the white arrow.  
 
 
1
H 
15
N HSQC. 
1
H 
15
N HSQC is a bidimensional heteronuclear spectrum that correlates the 
hydrogen of an amide group to the attached nitrogen.  Magnetization in transferred via J-
coupling JHN=90Hz from hydrogen to nitrogen. Chemical shift evolves on the nitrogen and 
magnetization is then transferred back to hydrogen for detection [Figure 73]. The position of 
the peak inside the spectrum (chemical shift) depends on the chemical environment of each 
HN.  
 
 
 
Figure 73. A schematic representation of the magnatization transfer in the 
1
H-
15
N HSQC: in pink the atoms 
observed and in black arrow how the magnetization is transferred. 
 
 
 124 
 
For this reason this spectrum is considered the protein fingerprint. In this spectrum are also 
visible the peaks of the side chains of glutamine, asparagine and tryptophan [Figure 74]. 
 
 
 
Figure 74. An example of 
1
H-
15
N HSQC spectrum of a protein. The usual position of the side chains of 
histidine and tryptophan are highlighted with the blue circle, the side chains of asparagine and glutamine in red 
one, each group HN group display two peaks with the same 
15
N resonance and two different 
1
H chemical shifts. 
The arginine side chains Nε-Hε are highlights with the red circle. 
 
 
1
H-
1
H TOCSY. It is a 2D homonuclear experiment. Magnetization is transferred along the 
1
H 
nuclei belonging to the same molecule or aminoacidic residue, through homonuclear scalar 
coupling and then it is detected from all the 
1
H nuclei. The sample is not labelled and this 
spectrum is useful to recognize the hydrogen belonging to the same spin system. This 
spectrum is acquired both in H2O and in D2O solvent. The spectrum acquired in D2O results 
to be simple as protons of HN groups exchange with 2H of the solvent and thus disappear 
ingfrom the spectrum when thery are not proteceted. 
 
 
1
H-
13 
C HSQC. This spectrum is the carbon equivalent of the 
1
H-
15
N HSQC. Magnetization is 
transferred from hydrogen to carbon and then back to the hydrogen for detection [Figure 75]. 
All 
1
H 
13
C group are observed.  
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Figure 75. The schematic representation of the transfer of magnetization of 
1
H-
13
C HSQC: in pink the 
atoms observed and in black arrow how the magnetization is transferred. 
 
 
1
H-
1
H NOESY. On the contrary of the previous described spectra, in 
1
H-
1
H NOESY 
magnetization is transferred between all proton through the dipolar coupling interactions 
among the nuclear spins that are close in the space [Figure 76]. This spectrum is helpful both 
to assign resonances and to get structural  restraints between protons. 
 
 
 
Figure 76. The schematic representation of the transfer of magnetization in 
1
H-
1
H NOESY: in pink the atoms 
observed and in black arrow how the magnetization is transferred. 
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8.1.6 Three -dimensional (3D) NMR experiments 
 
 
The pulse sequence for a 3D experiment can be easily constructed from the 2D one inserting 
an additional indirect evolution time and a second mixing period between the first mixing 
period and the direct data acquisition. Each of the different indirect time periods (t1, t2) is 
incremented separately [Figure 77]. 
 
 
 
Figure 77. The schematic pulse sequence of 3D spectrum. 
 
 
A 3D spectrum can be seen as a 2D spectrum which was extended into a third dimension in 
order to have a spread of the peaks.  
Most NMR spectra used for triple resonance backbone assignment have a 
1
H, 
15
N and 
13
C 
dimension each. Several other types of spectra as 3D NOESY and HCCH- TOCSY spectra 
have two 
1
H dimensions and one 
15
N or 
13
C dimension.  
 
 
HNCA. Magnetization in transferred from 
1
H to 
15
N and then via the JCα J-coupling 
(JNCα=20.8Hz) to the 13Cα and then back again to 
15
N and 
1
H for detection [Figure 78]. 
Chemical shift evolves for 
1
HN as well 
15
NH and 
13Cα, resulting in a 3D spectrum. The amide 
nitrogen is coupled both to the Cα of its own residue and to the Cα of the preceding residue, 
both these magnetization transfers occur and peaks for both Cα nuclei are visible in the 
spectrum. The coupling to the directly bonded Cα is stronger, hence the corresponding peaks 
will appear with stronger intensity. 
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Figure 78. The schematic representation of the magnetization transfer in HNCA: in pink the atoms 
observed and in black arrow how the magnetization is transferred. 
 
 
HNCACB. Magnetization is transferred from 
1Hα and 1Hβ to the 13Cα and 13Cβ respectively, 
and then from the 
13Cβ to the 13Cα. From 13Cα the magnetization is transferred to 15Ni from 
both 
13Cαi and 
13Cαi-1. Thus for each NH four peaks are visible: the Cα and the Cβ from the 
same residue as the NH which display a strong intensity and the Cα and the Cβ of the 
preceding one which display weak intensity. 
 
 
 
Figure 79. The schematic representation of the magnetization transfer in HNCACB: in pink the atoms 
observed, the atoms in which the magnetization flows but they are not observed and in black arrow how the 
magnetization is transferred.  
 
 
HN(CO)CACB. The magnetization is transferred from the Hα and Hβ to 13Cα and 13Cβ 
respectively and then from the 
13Cβ to 13Cα. From here it is transferred to 13CO, then to 15NH 
and finally to 
1
HN for detection. Chemical shift evolves simultaneously on the 
13Cα and 13Cβ 
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so they appear in one dimension. Chemical shift evolves in the other two dimension the 
15
NH 
and 
1
HN, but it does not evolve on 
13CO. For each NH group the peaks of the Cα and Cβ of 
the preceding residue are visible. 
 
 
 
Figure 80. The schematic representation of the magnetization transfer in HN(CO)CACB: in pink the atoms 
observed, in blue the atoms in which the magnetization flows but they are not observed and in black arrow how 
the magnetization is transferred. 
 
 
HNCO. Magnetization is transferred from 
1
H to 
15
N and then selectively to the carbonyl 
13
C 
via J-coupling JHN-CO=15 Hz, and then back for detection. For each HN group there is only 
one CO peak visible belonging to the preceding residue. This spectrum is used to obtain the 
CO chemical shifts which are employed in software as TALOS+ to help the prediction of 
dihedral angles and of the secondary structures. 
 
 
 
Figure 81. The schematic representation of the magnetization transfer in HNCO: in pink the atoms 
observed and in black arrow how the magnetization is transferred. 
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HNHα. The HNHα is a 3D spectrum in which magnetization is transferred from 1H and 15N 
and then selectively to the backbone 
1Hα via three-bonds J-coupling 3J(HNHα)57. 
Magnetization is then transferred back via 
15
N to 
1
H for detection. Hence for each amide 
group the spectrum displays one diagonal peak and one cross peak, corresponding to the 
resonance of the amide proton and of the α proton of the same residue, respectively.  
 
 
CC(CO)NH. Magnetization is transferred also in this case through scalar coupling from the 
side-chain 
1
H nuclei to the attached 
13
C nuclei. Then isotropic 
13
C mixing is used to transfer 
magnetization between the 
13
C nuclei. From here, magnetization is transferred to 
13
CO, and 
then to 
15
N
H 
and finally to 
1
H
N
 for detection. Chemical shift evolves simultaneously on all 
side-chain 
13
C nuclei, as well as 
15
N
H
 and 
1
H
N
 nuclei, resulting in a 3D spectrum. For each 
NH group there is one peak for every 
13
C nucleus of the side chain of the preceding residue. 
 
 
 
Figure 83. The schematic representation of the magnetization transfer in CC(CO)NH: in pink the atoms 
observed, in blue the atoms in which the magnetization flows but they are not observed and in black arrow how 
the magnetization is transferred. 
 
 
HCC(CO)NH. Magnetization is transferred from the 
1
H nuclei to their attached 
13
C nuclei. 
Then isotropic 
13
C mixing is used to transfer magnetization between the 
13
C nuclei. From 
here, magnetization is transferred to 
13
CO, then to 
15
N
H 
and finally to 
1
H
N
 for detection. 
Chemical shift evolves simultaneously on all side-chain 
1
H nuclei, as well as 
15
N
H
 and 
1
H
N
 
nuclei, resulting in a 3D spectrum with one nitrogen and two hydrogen dimensions. For each 
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HN group the 
1
H chemical shifts from the whole side chain of the preceding residue are 
visible. 
 
 
 
Figure 84. The schematic representation of the magnetization transfer in HCC(CO)NH: in pink the atoms 
observed, in blue the atoms in which the magnetization flows but they are not observed and in black arrow how 
the magnetization is transferred. 
 
 
1
H-
15
N-HSQC-NOESY (3D). Magnetization is transferred through dipolar interactions 
between all protons using the NOE effect (paragraph 9.1.3). Then magnetization is transferred 
to neighbouring 
15
N nuclei and back to 
1
H for detection. For each NH group, NOE peaks of 
1
H
N
 atom to all other 
1
H atoms close by are visible. 
 
 
 
Figure 85. The schematic representation of the magnetization transfer in 
1
H-
15
N-HSQC-NOESY: in pink 
the atoms observed and in black arrow how the magnetization is transferred. 
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1
H-
13
C-HSQC-NOESY (3D).  Magnetisation is transferred between all protons exploiting the 
NOE effect (paragraph 9.1.3). Then magnetisation is transferred to neighbouring 
13
C nuclei 
and back to 
1
H for detection. Transfer either occurs to/from the aliphatic 
13
C nuclei or to/from 
aromatic 
13
C nuclei (but not both) depending on the 
13
C frequency used during the pulse 
sequence. For each CH group, NOE peaks of the 
1
H
C
 atom to all other 
1
H atoms nearby are 
visible. A double set of peaks usually arises from a CH2 group in which the two 
1
H have 
different chemical shifts. 
 
 
 
Figure 86. The schematic representation of the magnetization transfer in 
1
H-
13
C-HSQC-NOESY: in pink 
the atoms observed and in black arrow how the magnetization is transferred. 
 
 
 
8.1.7 Structure calculation 
 
 
The standard procedure to determine the solution structure of a protein from NMR data is to 
minimize an objective function which incorporates experimental data (intensities of assigned 
NOE cross-peaks, dihedral angles, residual dipolar couplings) and physical knowledge 
(quantified by a molecular dynamics force field). We used ARIA 2.1.3 
62
 to calculate the 
solution structure of NPHP11-115.   
Distances are derived from NOE cross-peak volumes (V) to generate restraints for structural 
calculations by converting this information to a target distance D using the following 
equation:  
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D = ( α–1 V ) –1/6           eq. 15 
 
The calibration factor α depends on the properties of the system under investigation and on 
the experimental setup, and cannot be measure directly. It is estimated for each spectrum by 
ARIA during a calibration step. Rather than a definite value, the distance is restrained to an 
interval comprised in a range defined by a lower distance bound, L=max(0, D–Δ), and an 
upper distance bound, U=D+Δ (where Δ=0.12D2).  
ARIA introduces the concept of ambiguous distance restraint (ADR), which allows to 
combine more than one assignment in a single restraint according to equation 16 
 
  6/16  i iambig dd          eq. 16  
 
where the overall distance dambig is treated as having contributions from all possible 
assignments, each contributing with a distance di.  
The assignment possibilities are filtered consistently with the molecular conformations 
calculated. Each cycle of ARIA iterative procedure is constituted by three steps:  
 
 independent calibration of each NOESY spectrum in order to calculate the calibration 
factor α  
 
 detection of wrong assignments and noise peaks restrains are subjected to violation 
analysis. Each restraint distance’s bounds (L and U) are compared to the corresponding 
distances found in the ensemble. “Violation” occurs when the distance found in the structures 
deviates from the bounds by more than a user-defined violation tolerance in a percentage of 
structures higher than the user-defined violation threshold  
 
 calculation of the new ensemble of structures. Restraints from different spectra are 
merged and multiple structures compatible with restraints and empirical information are 
produced by means of simulated annealing. The temperature is increased in order to allow the 
sampling of high energy conformations aiming to overcome energetic barriers and escape 
local minima. Subsequently, the temperature is slowly reduced searching for the conformation 
corresponding to the global energetic minimum.  
From the second iteration on, prior the calibration the program performs an analysis of the 
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previously calculated structures. The conformers with lowest energy (“converged 
conformers”) are selected and used for the further analyses. Finally, the best structures of the 
final iteration are subjected to a refinement in a shell of water molecules via a short trajectory 
with a full MD force field.  
Finally ARIA uses the programs WHAT IF, PROCHECK and PROSA II to evaluate the 
quality of  both the last interaction structure ensemble and the solvent-refined ensemble, For 
every program separate report files are stored. 
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8.2.Metabonomics and Metabolomics appendix 
 
 
8.2.1 Metabonomics and metabolomics 
 
 
Metabonomics and metabolomics are the youngest “omics” sciences that study the 
metabolome
89
. The metabolome is constituted by about 2200 small molecules with low 
molecular weight (<1000 Da) involved in highly complex and organized biochemical 
networks. They include  metabolic substances and products such as lipids, small peptides, 
vitamins and other protein cofactors
90
. Moreover the metabolome is dynamic and it responses 
more quickly than genome, trascriptome and proteome to changes caused by drugs, 
environment and disease, but at the same time it can complement information derived from  
others “ –omics” sciences to have a global view on the system biology 90. 
 
 
 
Figure 87. The relationship between the genomics, transcriptomics, proteomics and metabolomics. [Figure 
from Ma Y. et al. Mol. Biol. Rep. 2012] 
 
 
Nowadays the terms metabolomics and metabonomics are often interchangeable referring to 
multi-component analysis of metabolites in a biological system. Originally the two definitions 
were slightly different: metabolomics was defined as the global analysis of all metabolites in a 
sample, while metabonomics comprised the analysis of metabolomic responses to drugs or 
disease
91
.  
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Through metabolomics we can study biofluids, cells or tissues in order to discover biomarkers 
for a particular disease or to understand the behavior of a particular tissue and/or biofluid 
under defined stimuli. For these reasons the data must be reproducible, hence the accurate and 
correct manipulation and storage of biological sample are essential and they represent a 
critical step
92
. Moreover, another essential and critical step in metabolomics studies is the 
experimental design. During this step the experimental conditions and the adequate sample 
size are decided in order to minimize the variability due to sample manipulation.  
The study of the metabolome can be usually divided in four steps 
93
: 
 
 Metabolic profiling: identification and quantification of a selected number of predefined 
metabolites related to a specific metabolic pathway; 
 
 Metabolic fingerprinting: global and rapid analysis to classify the sample, usually 
applied as a screening tool to discriminate samples belonging to different classes; 
 
 Metabolic footprinting: analysis of the (exo)metabolites secreted/excreted by an 
organism, such as conditional medium in the presence of cells; 
 
 Metabolite target analysis: qualitative and quantitative analysis of one, or several, 
metabolites belonging to a specific metabolic pathway. 
 
The pipeline to design, perform and analyze metabolomic data is described in the 
following
94
[Figure 88]. 
The two most widely used analytical tools for metabolomic studies are: mass spectrometry 
(MS) and nuclear magnetic resonance (NMR). These two complementary techniques have 
different experimental and technological features and applications depending on the specific 
questions and focus of the experiment 
92
. 
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Figure 88. Schematic workflow for metabolomic analysis. [Figure from Smolinska A., et al., Analytica 
Chimica Acta 2012]. 
 
 
 
8.2.2 Mass spectrometry 
 
 
Mass spectrometry (MS) is more sensitive than NMR but the metabolites must be separated 
from biological fluid before detection, typically by using high-performance liquid 
chromatography (HPLC) or gas-chromatography (GC) . Recently, technological advances in 
separation, ion sources and mass analyzers have increased the sensitivity, selectivity, 
specificity and speed of metabolites detection and identification by MS. Manipulation of 
samples can be misleading because compound moreover information could be lost because 
this technique disrupts the structures and the interactions of molecular complexes
82
. 
The global analysis of metabolites by MS should consider: the efficient and unbiased 
extraction of metabolites from the sample, the separation or fractionation of the analytes by 
chromatography, the ionization of the molecules, detection of signals and identification of 
them. 
There are many software developed to analyze MS spectra that are capable to filter noise, 
detect peaks (find the peaks corresponding to the same compounds, mass-to-charge ratio, 
m/z), alignment and normalization (adjusting the intensities within each sample run by 
reducing the systematic error) 
92
.  
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8.2.3 Nuclear magnetic resonance (NMR) 
 
 
NMR spectroscopy is a non-destructive, non-invasive, highly selective and fast method able 
to analyze samples without previous extensive pre-processing and separation, but it is less 
sensitive than MS. The results of NMR measurements have proven highly replicable across 
laboratories and instruments 
92
. NMR can provide measurements for different types and sizes 
of both polar and non-polar molecules simultaneously at a particular time point providing a 
metabolic “snapshot”. In addition the instruments are highly versatile and users can obtain 
spectral information for different nuclei, typically for 
1
H, 
13
C, 
15
N, 
31
P nuclei, both in liquids 
and in solids using high-resolution solution NMR spectroscopy or high resolution magic angle 
spinning (HRMAS), respectively. The employment of HRMAS for the metabolic analysis on 
the whole cells and tissues avoids losses due to the extraction protocol compared with the 
solution NMR. 
 
 
 
8.2.4 NMR spectra 
 
 
1D spectra. Generally the metabolomic samples, such as urine, blood, tissue and cells, 
contains both low and high molecular weight components and an high amount of water.  
The large NMR signal of the water has to be eliminated using appropriate standard NMR 
solvent suppression methods, generally the most used methods is the presaturation. In Figure 
89B the schematic representation of a pulse sequence of a 1D spectrum with  presaturation 
during  preparation. 
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Figure 89. The schematic pulse sequence of the 1D 
1
H spectrum A without presaturation B with 
presaturation. 
 
 
For the presence of the low and high molecular weight components in metabolomic samples 
the monodimensional spectrum presents a wide range of signal line widths [Figure 90]: broad 
lines from proteins and lipoproteins signals strongly contribute to 
1
H NMR spectra, with high 
signal overlap deriving  resulting in overcrowded spectra. 
Often spectra are acquired through edited pulse sequences on the basis of molecular diffusion 
or NMR relaxation in order to enhance the contribution of macromolecules or the signal of 
small molecules
95
. Generally for each sample three 1D 
1
H NMR spectra are acquired: 
 
 1D nuclear Overhauser effect with presaturation (1D NOESY-presat): unedited 
spectrum in which all metabolites are detected [Figure 90 A] 
 
 1D Carr-Purcell-Meiboom-Gill (CPMG) spin-echo sequence: edited for T2 relaxation, 
to allow detection of only small molecules whereby the broad signals due to the contribution 
of lipids and proteins are removed [Figure 90 B] 
 
 1D diffusion spectrum: edited for the diffusion coefficient of the molecule in which 
only the macromolecules, as lipids and proteins, are detected, removing  signals from small 
molecules[Figure 90 C]. 
 
 
 139 
 
In the metabolomic samples a reference compounds is always added as chemical shift 
reference: 3-trimethylsilylpropionic acid (TSP) or 2,2-dimethyl-2-silapentane-5- sulfonate 
sodium salt (DSS) for samples in aqueous solvent, tetramethylsilane (TMS) for ones in 
organic solvents
95
. 
The peak integral of each molecule is related both to the concentration of the substance in the 
sample and to the number of protons that gives rise to the peak
95
. Hence the absolute 
concentration can be calculated from the peak integral in several manners: 
 
 Using the internal standard with a known concentration; 
 
 Using an external standard with known concentration. 
 
 
 
Figure 90. The 1D 
1
H NMR spectra generally acquired for metabolomics analysis. A. 1D 
1
H Noesy B. 1D 
1
H cpmg edited for T2 C. 1D 
1
H diffusion edited for the diffusion coefficient. 
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2D NMR spectra.To identify the molecules of a metabolic sample the 1D spectra are not 
sufficient, therefore 2D spectra are acquired to increase the signal dispersion and elucidate the 
connectivity between signals
95
. The 2D experiments generally acquired are: 
 
 J-resolved: this experiment yields the information on the multiplicity and coupling 
patterns of resonance [Figure 91 A]; 
 
 TOtal Correlation Spectroscopy (TOCSY): this experiments provides spin-spin 
coupling connectivity identifying the hydrogens belonging to the same spin system. [Figure 
91 B]; 
 
 Heteronuclear Single Quantum Coherence (HSQC): the spectrum can be used  to detect 
the hydrogens and heteroatomes(
15
N and 
13
C) linked by one bond, usually for metabolomic 
analysis the 
1
H 
13
C HSQC is acquired. The magnetization is transferred from 
1
H to 
13
C though 
chemical bonds, hence in the spectrum all carbons connected to a proton are displayed [Figure 
91 C].  
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Figure 91. The 2D  NMR spectra generally acquired for metabolomics analysis. A. 2D J-resolved
 
B. 2D 
1
H-
1
H TOCSY C. 2D 
13
C- 
1
H HSQC. 
 
 
 
8.2.5 Data preprocessing 
 
 
Data preprocessing is an intermediate step between row spectra and data analysis. The main 
objective of data preprocessing is to transform the data in such a way that the samples in the 
dataset are comparable, to facilitate  data analysis. This step, like the experimental design, is 
crucial
94
. 
Spectra from MS or NMR analysis are processed in order to remove the noise deriving from 
spectra acquisition through  baseline removal. In NMR and MS spectra the baseline 
distortions can be corrected in  different ways through mathematical methods based on 
polynomial fitting.  
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Usually spectra overlays do not show perfect alignment, this phenomenon is often caused by 
instrumental factors, changes of the pH and temperature. The MS spectra are generally 
aligned on the time scale choosing a linear variables for each spectrum, while the alignment 
of the NMR spectra is set on an internal reference signal. This type of alignment is often not 
sufficient as it can only remove the global shift but not the local one, for this reason there are 
many software that implement the local alignment of the spectra, as MestreLab software 
48
. 
A further preprocessing step of NMR spectra is the binning. In binning the NMR spectra are 
divided into segments (so called bins or buckets) and the total area within each bin is 
calculated to represent the original spectrum. Therefore, some minor peaks shifts can be 
removed by spectral binning. There are many types of spectral binning, the most common 
type is an equidistant binning of 0.04 ppm. This indicates that every spectrum is divided into 
evenly spaced integral regions with spectral width of 0.04 ppm. The disadvantage of this 
equidistant binning is the lack of flexibility of the boundaries. If a peak is split into two bins, 
the peak frequency may significantly influence the data analysis. To prevent the peaks being 
split by the boundaries of bins, methods which are based on non-equidistant spacing have 
been proposed, such as adaptive-intelligent binning (AI-binning) 
96
and Dynamic adaptive 
binning
86
. These methods take into account peak positions and thus focus on a better peak 
definition. Therefore, it is possible to obtain binning where one bin covers only a complete 
peaks. 
 
Normalization and scaling transformation. This step of preprocessing tries to account for the 
variations of the overall concentrations of the samples. The main aim is to make all the 
samples comparable with each other by for instance removing or minimizing the total amount 
of material for samples or metabolite dilution.  
The MS spectra are generally normalized for an internal known standard added to sample 
before or after extraction
95
, whereas the most common method to normalize the NMR spectra 
is the “integral normalization”. This standard method normalizes the individual spectra to 
constant total integrated intensity across the whole profile
94
. 
The concentration of metabolites in biofluids can span different orders of magnitude. 
Moreover, the variation in metabolites level is often linked to concentration in such a way that 
metabolites with highest concentrations strongly influence data analysis. For this reason it is 
very important to scale the metabolites concentration before analysis to avoid a bias from the 
most abundant metabolites. 
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There are many scaling methods, the most commonly used are the mean-centering, the 
autoscaling and the pareto scaling
97
. 
The mean-centering method converts. all the concentrations into fluctuations around zero 
instead. The method cannot be sufficient if the data contain sub populations with different 
variability, for this reason  the method is usually used in combination with other scaling 
methods. 
 
iijij xxx 
~            eq. 17 
 
Autoscaling, also called unit or unit variance scaling, uses the standard deviation as the 
scaling factor through equation 18. After the application of this scaling all metabolites have a 
standard deviation equal to one.  
 
i
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
~            eq. 18 
 
Pareto scaling is very similar to autoscaling, the square root of standard deviation is used as 
the scaling factor. In this way the large fold changes are decreased more than the small fold 
changes, consequently the large fold changes are less dominant compared to the raw data. 
 
i
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~           eq. 19 
 
 
 
8.2.6 Data analysis 
 
 
Multivariate statistical methods are used to analyze the great amount of data  deriving  from 
the metabolomic analysis, in order to provide the maximum information out of the system 
under study. Analysis can be performed with supervised and unsupervised methods. 
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Unsupervised analysis. Usually, this kind of analysis is used as a method to explore and 
discover the overall structure of the data without any additional information, finding trends 
and groups in the data. The most used methods is the principal component analysis (PCA). 
PCA converts the multidimensional data space into a low-dimensional model plane. This 
technique expresses most of the variance in a dataset using a smaller number of factors, the so 
called principal components (PCs), which account for a sequentially minor proportions of the 
total variance between analyzed samples
96
.  
Each PC is orthogonal to the other PCs and therefore contains different information. The 
variation in spectral data is described by a few PCs compared to the number of original 
variables, thus enabling the detection of trends and groupings in the data. 
The result of PCA analysis is displayed through two plots: the score and the loading plot. 
The score plot displays the samples as points in the new plane and shows how they are related 
to each other. Hence those points which cluster together have similar profiles, on the contrary, 
objects that lie far away are characterized by different properties.  
The loading plot describes the way in which the old variables are linearly combined to new 
variables (PCs) and indicates which variables have the greatest contribution in the new 
reference system. 
 
Supervised analysis. Differently from unsupervised methods, supervised techniques require  
additional information on experimental details (e.g. samples classification). Several 
supervised techniques have been developed for driving  statistical analysis when experimental 
perturbations cannot affect the total variance of the system or when technical noise covers 
experimental information. 
The most largely used supervised multivariate techniques is partial least square (PLS) analysis 
and its classification strategy derivative, PLS discriminant analysis (PLS-DA)
98
. But these 
statistical techniques were not used in this metabolomic work.  
 
 
 
8.2.7 Identification of metabolites 
 
 
Analyzing the 1D and 2D NMR spectra and the MS spectra it is also possible to identify the 
metabolites contained in a biofluid or tissue.  
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The identification of the metabolites usually occurs comparing the acquired spectra with the 
data stored in public databases of known metabolites 
99
[Table 13]. Nowadays all the public 
databases contain structural and chemical information of the metabolite and the relative NMR 
and/or MS spectrum, but some of them are specific for a particular biological system, such as 
human, yeast or bacteria. They contain also biological information, including the metabolic 
pathways in which the metabolites are involved. In particular the Human Metabolome 
DataBase (www.hmdb.ca) 
100
contains structural,  chemical, biological and clinical information 
of the metabolites detected in NMR and MS spectra,  
  
 
 146 
 
Table 13. List of the metabolomic database available. Except NIST08 and MeMO, the other database are free. 
[Table from  Go E. P. 2010, J. Neuroimmune Pharmacol.] 
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